Enantioselective formal (3+3) cycloaddition of bicyclobutanes

with nitrones enabled by asymmetric Lewis acid catalysis

Wen-Biao Wu,^{1,2,3,4} Bing Xu,^{4,5} Xue-Chun Yang,^{1,4} Feng Wu,¹ Heng-Xian He,¹ Xu Zhang,² and Jian-Jun Feng^{*1}

¹State Key Laboratory of Chemo/Biosensing and Chemometrics, Advanced Catalytic Engineering Research Center of the Ministry of Education, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, P. R. China.

²School of Chemistry & Chemical Engineering, Yangzhou University, Yangzhou, 225002, P. R. China.
³School of Physics and Chemistry, Hunan First Normal University, Changsha, 410205, P. R. China.
⁴These authors contributed equally to this work.

⁵Department of Chemistry, Fudan University, Shanghai, 200438, P.R. China.

* Corresponding Author (Jian-Jun Feng): jianjunfeng@hnu.edu.cn

Supplementary information

Table of Contents

1. Supplementary Methods	S2
1.1 General Information	S2
1.2 Optimization Study	S3
1.3 General Procedure for the Enantioselective (3+3) Cycloadditions (GP1) S7
1.4 General Procedure for the Synthesis of New Bicyclobutanes (GP2)	S7
1.5 Scale-Up Experiment	S8
1.6 Synthetic Transformations	S9
1.7 General Procedure for the Synthesis of Chiral Ligands	S13
2. Supplementary Discussion	S14
2.1 Unsuccessful BCB Substrates and Control Experiments	S14
2.2 Non-Linear Effect Study	S16
2.3 Proposed Catalytic Cycle and Computed Transition Structures	S17
2.4 Characterization Data of the New BCBs and Products	S18
3. X-Ray Crystallography	S73
4. Supplementary NMR and HPLC Spectra	S75
5. Supplementary Computational Details	S201
6. Supplementary References	S201

1. Supplementary Methods

1.1 General Information

All reactions were performed in flame-dried glassware using conventional Schlenk techniques under a static pressure of nitrogen unless otherwise stated. Liquids and solutions were transferred with syringes. Bicyclo[1.1.0]butanes (BCBs)^[1-4] and nitrones ^[5-6] were prepared according to reported procedures. Co(OTf)₂ (98%, *Bide* Chemical Company) and other commercially available reagents were purchased from Leyan, Energy Chemical and Bide Chemical Company and used as received. The solvents (CH₂Cl₂, 1,2-dichloroethane, Et₂O, THF and toluene etc.) were dried and purified following standard procedures. PhCI and Ethyl acetate (EtOAc) were purchased from Energy Chemical (99%, Extra Dry) and used as received. Technical grade solvents for extraction or chromatography (Petroleum ether, CH_2CI_2 , and ethyl acetate) were distilled prior to use. Analytical thin layer chromatography (TLC) was performed on silica gel 60 F254 glass plates by Merck. Flash column chromatography was performed on silica gel 60 (40-63 µm, 230-400 mesh, ASTM) by Grace using the indicated solvents. ¹H, ¹³C NMR spectra were recorded in CDCl₃ on Bruker AV400 or 600 instruments. Chemical shifts are reported in parts per million (ppm) and are referenced to the residual solvent resonance as the internal standard (CDCl₃: δ = 7.26 ppm for ¹H NMR and CDCl₃: δ = 77.0 ppm for ¹³C NMR). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplett, q = quartet, m = multiplet), coupling constants (Hz), and integration. The full-scan mass spectra were taken on a hybrid quadrupole-orbitrap mass spectrometer equipped with a heated electrospray ionization source (ThermoFischer Scientific, Bremen, Germany). Chiral HPLC analysis was performed on a Shimadzu LC-20AD instrument using Daicel chiral columns at 35 °C and a mixture of HPLC-grade hexanes and isopropanol as eluent. Acknowledgement: the ¹H, ¹³C NMR spectra, single crystal X-ray diffraction and HRMS (ESI) were performed at Analytical Instrumentation Center of Hunan University. The absolute configuration was determined by single crystal X-ray diffraction analysis on Rigaku XtaLAB PRO MM003-DS dual system with a Cu micro-focus source. Diffraction data was collected at 173 K on a Rigaku XtaLAB PRO MM003-DS dual System with a Cu micro-focus source.

1.2 Optimization Study



Supplementary Figure 1. Screening of chiral ligands for the enantioselective (3+3) cycloaddition of BCB **1a** and nitrone **2a**^[a]. [a] Reaction conditions: **1a** (0.10 mmol, 1.0 equiv), **2a** (0.12 mmol, 1.2 equiv), Lewis acid (10 mol%) and Ligand (12 mol%), CH₂Cl₂ (2 mL), 25 °C, under N₂ for 24 h. The yields of **3aa** was determined by ¹H NMR with CH₂Br₂ as an internal standard. The *ee* value was determined by chiral HPLC with hexane/2-propanol. The CAS number of the ligand is in parentheses. [b] The ligands **L1-4** and **L13-19** were purchased from *Bide* Chemical Company and used as received.



Supplementary Figure 2. Screening of chiral ligands for the enantioselective (3+3) cycloaddition of BCB **1a** and nitrone **2b**^[a]. [a] Reaction conditions: **1a** (0.10 mmol, 1.0 equiv), **2b** (0.12 mmol, 1.2 equiv), $Zn(ClO_4)_2 \cdot H_2O$ (10 mol%) and Ligand (12 mol%), CH_2Cl_2 (2 mL), 25 °C, under N₂ for 24 h. The yields of **3ab** was determined by ¹H NMR with CH_2Br_2 as an internal standard. The ee value was determined by chiral HPLC with hexane/2-propanol. The CAS number of the ligand is in parentheses. [b] The ligands **L4-9** and **L22-28** were purchased from *Bide* Chemical Company and used as received. The ligands **L29** was synthesized according to the literature^[7]. The ligands **L8** and **L30** were synthesized according to the literature^[8]. The ligands **L9-12** were synthesized according to the literature^[9-10]

Ph	N +	⊖ O ⊕ Bn	Lewis acid (10 mol%) Ligand (12 mol%)		Bn N Ph
		Ph ^M H	solvent, 25 °C, :	24 h l	Ph Z'
1a	Ζ.	2b			3ab
Entry	Lewis acid	Ligand	solvent	Yield (%) ^[b]	ee (%) ^[c]
1	Eu(OTf)₃	L9	CH_2CI_2	90	2
2	Ga(OTf)₃	L9	CH_2CI_2	99	0
3	Sc(OTf) ₃	L9	CH_2CI_2	66	17
4	Zn(OTf) ₂	L9	CH_2CI_2	51	90
5	Ni(OTf) ₂	L9	CH_2CI_2	95	80
6	Cu(OTf) ₂	L9	CH_2CI_2	89	65
7	Fe(OTf) ₃	L9	CH_2CI_2	84	14
8	Mg(OTf) ₂	L9	CH_2CI_2	45	23
9	Co(OTf) ₂	L9	CH_2CI_2	95	93
10	Co(OTf) ₂	L9	EtOAc	96	92
11	Co(OTf) ₂	L9	toluene	87	81
12	Co(OTf) ₂	L9	THF	82	91
13	Co(OTf) ₂	L9	1,4-dioxane	92	84
14	Co(OTf) ₂	L9	DCE	93	91
15	Co(OTf) ₂	L9	CH₃CN	60	59
16	Co(OTf) ₂	L9	PhCl	85	94
17	Co(OTf) ₂	L10	CH_2CI_2	98	99
18 ^[d]	Co(OTf) ₂	L10	CH_2CI_2	88	99
19 ^[e]	Co(OTf) ₂	L10	CH_2CI_2	99	99
20	Co(OTf) ₂	L10	CHCI ₃	90	99
21	Co(OTf) ₂	L10	CH ₂ Cl ₂ :HFIP (3:1, v/v)	15	96
22 ^[f]	Co(OTf) ₂	L10	CH_2CI_2	99	97
23 ^[g]	Co(OTf) ₂	L10	CH_2CI_2	75	97
24	Co(OTf) ₂	-	CH_2CI_2	99	-

Screening of Lewis acid and solvent for the Supplementary Table 1. enantioselective (3+3) cycloaddition of BCB 1a and nitrone 2b^[a]

[a] Reaction conditions: **1a** (0.10 mmol, 1.0 equiv), **2b** (0.12 mmol, 1.2 equiv), Lewis acid (10 mol%) and ligand (12 mol%), solvent (2 mL), 25 °C, under N2 for 24 h. [b] Determined by ¹H NMR with CH₂Br₂ as an internal standard. [c] Determined by chiral HPLC with hexane/2-propanol. [d] At 0 °C. [e] At 40 °C. [f] 4 ÅMS (50 mg) was added. [g] H₂O (5 μL) was added.

 CH_2CI_2

 CH_2CI_2

 CH_2CI_2

No reaction

No reaction

-99

98

L10

ent-L10

Co(OTf)₂

Co(OTf)₂

25

26

27



Supplementary Figure 3. Enantioselective cycloaddition of BCB **1n** and nitrone **2b**^[a]. [a] Reaction conditions: **1n** (0.10 mmol, 1.0 equiv), **2b** (0.12 mmol, 1.2 equiv), $Zn(ClO_4)_2 \cdot H_2O$ (10 mol%) and **L5** (12 mol%), CH_2Cl_2 (2 mL), 25 °C, under N₂ for 24 h. The yield of **3nb** was determined by ¹H NMR with CH_2Br_2 as an internal standard. The *ee* value was determined by chiral HPLC with hexane/2-propanol.



Supplementary Figure 4. Influence of R¹ substituents in nitrones on background reaction ^[a]. [a] Reaction conditions: **1a** (0.10 mmol, 1.0 equiv), **2b** or **2d** (0.12 mmol, 1.2 equiv), Co(OTf)₂ (10 mol%), CH₂Cl₂ (2 mL), 25 °C, under N₂ for 20 min. The yields of **3ab** or **3ad** were determined by ¹H NMR with CH₂Br₂ as an internal standard.



1.3 General Procedure for the Enantioselective (3+3) Cycloadditions (GP1)

Under an atmosphere of N₂, to a 25 mL oven-dried Schlenk tube were added Co(OTf)₂ (7.1 mg, 0.020 mmol) and **L10** (17.1 mg, 0.024 mmol), followed by 2.0 mL of anhydrous CH_2CI_2 . The solution was stirred at 25 °C for 0.5 h, and then the BCBs **1** (0.20 mmol, 1.0 equiv) and nitrones **2** (0.24 mmol, 1.2 equiv) were added. Then the resulting mixture was stirred at room temperature for 16 h till full conversion of **1** by TLC analysis. After the solvent was removed under reduced pressure, the residue was directly subjected to a column chromatography purification using PE/EtOAc (4:1, v/v) as the eluent, to afford the desired product **3**.

1.4 General Procedure for the Synthesis of New Bicyclobutanes (GP2)



BCB esters **S1** were prepared according to literature procedures.^[1-4] Weinreb amide derived BCBs **S2** were synthesized as following: An oven-dried 100 mL round bottom flask equipped with a stir bar was cooled under vacuum. After backfilled with N₂ (x 3) and capped with a septum, BCB esters **S1** (5.00 mmol, 1.0 equiv) and THF (25.0 mL) were added. The reaction was cooled to 0 °C. MeNH(OMe)·HCI (585.0 mg, 6.00 mmol, 1.2 equiv) and PrMgCI (6.0 mL, 2.0 M in THF, 12.00 mmol, 2.4 equiv) were sequentially added to the solution. After stirred at the same temperature for 12 h, the reaction was quenched by saturated NH₄CI solution (20 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (25 mL), dried over anhydrous MgSO₄, filtered and concentrated by rotary evaporation. The crude Weinreb amide derived BCBs **S2** was directly used in next reaction.

An oven-dried 100 mL round bottom flask equipped with a stir bar was cooled under vacuum. After backfilled with N₂ (x 3) and capped with a septum, *N*-substituted imidazole derivatives (6.50 mmol, 1.3 equiv) and THF (20.0 mL) were added. The reaction was cooled to -78 °C. ^{*n*}BuLi (2.6 mL, 2.5 M in THF, 6.50 mmol, 1.3 equiv) was added to the solution. After stirred at the same temperature for 20 min, **S2** dissolved in THF (5.0 mL) was added. Next, the reaction was warm to room temperature and stirred overnight. Then, the reaction was quenched by saturated NH₄Cl solution (20 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (25 mL), dried over anhydrous MgSO₄, filtered and concentrated by rotary evaporation. The residue was purified by flash chromatography on silica gel (petroleum ether/EtOAc = 5/1) to afford a new kind of BCB **1**.

NOTE: the bicyclo[1.1.0]butanes (**1n-p**) equipped with an acyl pyrazole group were synthesized according to the literature^[11-12].

1.5 Scale-Up Experiment



Under an atmosphere of N₂, to a 100 mL oven-dried Schlenk tube were added $Co(OTf)_2$ (35.7 mg, 0.10 mmol, 10 mol%) and **L10** (85.0 mg, 0.12 mmol, 12 mol%), followed by 20.0 mL of anhydrous CH₂Cl₂. The solution was stirred at 25 °C for 0.5 h. Then the BCB **1n** (252.0 mg, 1.00 mmol, 1.0 equiv) and nitrone **2b** (253.2 mg, 1.20 mmol, 1.2 equiv) were added. The resulting mixture was stirred at room temperature for 16 h till full conversion of **1n** by TLC analysis. After the solvent was removed under reduced pressure, the residue was directly subjected to a column chromatography

purification using PE/EtOAc (20:1, v/v) as the eluent, to afford the desired product **3nb** (458.4 mg, 99% yield, 99% ee).

1.6 Synthetic Transformations



General Procedure for the conversion of 3nb or 3qb to aldehyde (GP3): The solution of LiAlH₄ (5.7 mg, 0.15 mmol, 1.5 equiv) in THF (2.0 mL) was cooled to -40 °C, and then a solution of **3** (0.10 mmol, 1.0 equiv) in THF (1.0 mL) was charged into the solution at -40 °C. After TLC analysis showed the starting material was consumed (30 min), HCl (aq. 1.0 M) was added at -40 °C and stirred for 15 min. The reaction mixture was directly filtered through celite, washed and extracted with EtOAc. The mixture was extracted with EtOAc (3 × 5 mL). Filtered and concentrated on rotavapor under reduced pressure. The residue was purification by flash chromatography on silica gel using petroleum ether/ethyl acetate (10/1) to afford **4** as a colorless oil.



Synthesis of (5): In a flame dried Schlenk flask, MeMgBr (3.0 M in Et₂O, 0.1 mL, 0.30 mmol, 3.0 equiv) was added portionwise to a solution of the **3ab** (44.9 mg, 0.10 mmol, 1.0 equiv) in dry THF (1.0 mL) at room temperature. The reaction was stirred for 1 hours, and monitored by TLC. Then aqueous saturated NH₄Cl solution (5 mL) was added to quench the reaction. The solution was extracted with ethyl acetate, washed with brine, dried over Na₂SO₄, filtered and concentrated on rotavapor under reduced pressure. The intermediate was dissolved with dry ethyl acetate (2.0 mL) and Mel (141.9 mg, 1.00 mmol, 10.0 equiv) was added. The reaction was heated at 60°C for 24 hours. And then, it was cooled down to room temperature and concentrated to

dryness. The residue was taken up in dry toluene (1.0 mL) and DBU (106.4 mg, 0.70 mmol, 7.0 equiv) was added. The mixture was heated at 80°C for 16 hours. The crude residue was purified by silica gel column chromatography (PE/EtOAc = 5:1) to afford **5** (28.7 mg, 75%, 99% ee) as a colorless oil.



Synthesis of (6): To a solution of **3nb** (46.3 mg, 0.10 mmol, 1.0 equiv) in MeOH (2.0 mL) was added Et₃N (30 μ L, 0.40 mmol, 2.0 equiv). The mixture was then stirred at 50 °C for 16 hour, and monitored by TLC. After the solvent was removed under reduced pressure, the residue was directly subjected to a column chromatography purification (PE/EtOAc = 20:1) as the eluent to afford **6** (41.0 mg, 99% yield, 99% ee) as a colorless oil.



Synthesis of (7): In a flame dried Schlenk flask, **3nb** (46.3 mg, 0.10 mmol, 1.0 equiv) was stirred in anhydrous THF (2.0 mL). The solution was cooled to 0 °C and MeMgBr (3.0 M in Et₂O, 0.1 mL, 0.30 mmol, 3.0 equiv) was added slowly. And then the reaction was stirred at room temperature for 1 hour. Finally, aqueous saturated NH₄Cl solution (2.0 mL) was added to quench the reaction. The mixture was extracted with EtOAc (3 × 5 mL). Filtered and concentrated on rotavapor under reduced pressure. The residue was purification by flash chromatography on silica gel using petroleum ether/ ethyl acetate (10/1) to afford **7** as a colorless oil (32.0 mg, 80% yield, 98% ee).



Synthesis of (8): To a solution of **3nb** (23.2 mg, 0.05 mmol, 1.0 equiv) in MeOH (5.0 mL) was added Pd(OH)₂/C (10 wt%) (5.0 mg). This flask was in a vacuum and back-filled with H₂ (1 atm). After being stirred at room temperature for 16 hour, the reaction solution was filtered, and the filtered-cake was washed with EtOAc (5.0 mL). The filtrate was evaporated under vacuo, and purified by silica gel column chromatography using petroleum ether/ethyl acetate (2/1) as the eluent to give the product **8** in 80% yield (15.0 mg). [α]_D²⁰ = +32.7 (*c* = 0.30, CHCl₃). The enantiomeric excess could not be determined using HPLC analysis with chiral stationary phases in our laboratory.



Synthesis of (9): To the solution of chroman-2-ylmethanamine hydrochloride (15.0 mg, 0.075 mmol) in toluene (1.0 mL) was added Et₃N (7.6 mg, 0.075 mmol), and the mixture was stirred at 35 °C for 30 min. **8** (16.0 mg, 0.04 mmol), 4 Å MS (50 mg) and TsOH·H₂O (11.9 mg, 0.06 mmol) was added to the solution, and the mixture was stirred at 100 °C for 16 h. Then, the mixture was cooled to 0 °C. MeOH (1.0 mL) and NaBH₄ (2.3 mg, 0.06 mmol) was added to the solution, and the mixture was stirred for 1 h at room temperature. The resulting solution was quenched with H₂O and extracted with EtOAc (3 × 5 mL). Filtered and concentrated on rotavapor under reduced pressure. The residue was purification by flash chromatography on silica gel using petroleum ether/ethyl acetate (3/1) to afford **9** as a colorless oil (20.0 mg, 93% yield).



Synthesis of (10): 8 (19.4 mg, 0.05 mmol) and 1-(2,3-dihydrobenzo[b][1,4]dioxin-5yl)piperazine hydrochloride (12.9 mg, 0.05 mmol) were mixed in 1,2-dichloroethane (2 mL) and treated with NaBH(OAc)₃ (15.9 mg, 0.075 mmol) and HOAc (20 μ L) under an atmosphere of argon. The reaction mixture was stirred at room temperature for 12 h. The resulting solution was quenched with 2 N NaOH (2.0 mL) and extracted with EtOAc (3 × 5 mL). Filtered and concentrated on rotavapor under reduced pressure. The residue was purification by flash chromatography on silica gel using petroleum ether/ethyl acetate (10/1) to afford **10** as a colorless oil (10.4 mg, 35% yield).



General Procedure for Copper-Catalyzed Alkyne–Azide Cycloaddition (GP4): A Schlenk tube is charged with **3as** (20.0 mg, 0.04 mmol, 1.0 equiv), Cul (0.8 mg, 0.004 mmol, 10 mol%), DIPEA (5.4 mg, 0.04 mmol, 1.0 equiv) and CH₃CN (1.0 mL). Then azide compounds (0.06 mmol, 1.5 equiv) was added. The reaction mixture is stirred at

room temperature for 5 h. The mixture is then concentrated under reduced pressure, and purified by silica gel column chromatography to give the product **11-12**.

1.7 General Procedure for the Synthesis of Chiral Ligands

1.7.1 The synthesis of L9-12 (GP5)



To the solution of pyridine-2,6-dicarbaldehyde (2.70 g, 20 mmol, 2.0 equiv) in anhydrous ethanol (40 mL) was added *L*-prolinamides (10 mmol, 1.0 equiv), and the reaction was heated and stirred at 60 °C for 3 h. After that, the reaction mixture was concentrated in vacuo to remove ethanol. The residue was purified by flash column chromatography (PE/EtOAc, 10/1-1/1, v/v) to give compounds **S5**.

In a round-bottomed flask containing a stir bar, compound **S5** (6.9 mmol, 1,0 equiv), **S6** (6.9 mmol, 1.0 equiv) AcOH (0.6 mL, 10.5 mmol, 1.5 equiv) and CH_2CI_2 (70 mL) were added. Then, the reaction was stirred at room temperature for 6-8 h. After that, the reaction mixture was quenched by saturated NaHCO₃ solution (20 mL). The organic layer was extracted with CH_2CI_2 (3 × 20 mL). Filtered and concentrated on rotavapor under reduced pressure. The resulting residue was purified by silica gel column chromatography to give ligands **L9-12**.

1.7.2 The synthesis of L21



To the solution of BINOL-bistriflate **S6** (2.75 g, 5.0 mmol, 1.0 equiv) in DMF (20 mL) was added $Pd(OAc)_2$ (56.5 mg, 0.25 mmol, 5 mol%), dppp (162.0 mg, 0.5 mmol, 10 mol%) and $Zn(CN)_2$ (292.5 mg. 2.5 mmol, 5.0 equiv). Then the reaction was heated and stirred at 120 °C for 48 h. After the reaction was cooled to room temperature, the reaction mixture was diluted with ethyl acetate, and washed with H₂O and brine. The mixture was then dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was further purified by flash chromatography (PE/EtOAc, 10/1, v/v) to give compounds **S7** (1.50 g, 99% yield).

To a 25 mL sealed tube were added ZnCl₂ (204.0 mg, 1.5 mmol, 5.0 equiv), **S7** (100.0 mg, 0.3 mmol, 1.0 equiv) and PhCl (3 mL). After the reaction mixture was stirred at room temperature for 10 min, (*R*)-2-amino-2-(4-fluorophenyl)ethan-1-ol (232.5 mg, 1.5 mmol, 5.0 equiv) was added to the tube. This tube was sealed and the reaction mixture was stirred at 120 °C for 4 days. The mixture was cooled to room temperature. Et₂NH (1 mL) was added to the tube, and the mixture was stirred at room temperature for 1.0 h. The residue was further purified by flash chromatography (PE/EtOAc, 4/1, v/v) to give ligand **L21** as a colorless oil (69.6 mg, 40% yield).

2. Supplementary Discussion

2.1 Unsuccessful BCB Substrates and Control Experiments

The (3+3) reaction of **2n** with N-phenyl nitrone **2d** yields the desired **3nd** with 28% ee. In contrast, the cycloaddition of **1a** and **2d** produces **3ad** with 94% ee under identical reaction conditions. Unfortunately, the current reaction did not apply to methylsubstituted BCB substrate **1r** and mono-substituted BCB substrate **1t**. The estersubstituted BCB **1u** was used in the (3+3) cycloaddition but did not produce any cycloadduct, indicating that the chelation of bidentate group to Lewis acid catalyst is essential. In the absence of nitrone, the reaction of BCB 1k resulted in a 70% recovery of the starting material with no detectable cyclobutene, potentially excluding the presence of carbocation species.



Supplementary Figure 5. Comparison of BCB with an acyl imidazole group and BCB with an acyl pyrazole moiety in stereocontrol and unsuccessful BCB substrates.

2.2 Non-Linear Effect Study

Supplementary Table 2. Tabulation of non-linear effects^[a]



[a] Reaction conditions: **1a** (0.10 mmol, 1.0 equiv), **2b** (0.12 mmol, 1.2 equiv), $Co(OTf)_2$ (10 mol%) and **L10** (12 mol%), CH_2Cl_2 (2 mL), 25 °C, under N₂ for 24 h. [b] Determined by chiral HPLC with hexane/2-propanol.



Supplementary Figure 6. Non-linear effect study.



2.3 Proposed Catalytic Cycle and Computed Transition Structures

Supplementary Figure 7. Proposed catalytic cycle

To unravel the origin of enantiocontrol, density functional theory (DFT) calculations were performed at PBE0/6-31G(d)-SDD level of theory, using **1a** and **2b** as the model substrates along with the Co(II)–L12 chiral system. As shown in Fig. 6 in the main text, transition states **Ts-S** and **Ts-R** leading to both products were located, in which divalent Co coordinated with two nitrogen and one oxygen atoms of **L12** as well as one oxygen and nitrogen atoms of **1a**, generating a square pyramidal geometry. The difference between the two activation barriers of the intramolecular nucleophilic cyclization for the two enantiomers was 2.2 kcal/mol, consistent with the excellent enantioselectivity experimentally observed. Moreover, noncovalent interactions between reactant fragment and **L12** in **Ts-S** and **Ts-R** were explored using independent gradient model based on Hirshfeld partition (IGMH) analysis. Three pairs of C–H•••O interaction existed in both **Ts-S** and **Ts-R**. Notably, in the favored transition state **Ts-S**, imidazolidone of **L12** engaged in C–H...π interaction with phenyl group of nitrone **2a**, likely dominating the preference for the nucleophilic attack of the enolate on the *Re*-face of nitrone **2a** to furnish the (S)-configuration of product **3ab**.

Based on the work of Deng^[6], Xie, and Guo^[5], as well as our DFT calculations, we have proposed a plausible catalytic cycle for the current (3+3) reaction. Initially, the

chiral Co(II)/L12 catalyst coordinates with the acyl imidazole moiety, activating BCB **1a**. Subsequently, the concerted nucleophilic ring-opening pathway of **1a** with **2b** generates the key intermediate **int-2**. The carbanion is then generated in situ to attack the *Re* face of the C=N double bond in the nitrone via **Ts-S**, leading to the formation of **int-2**. Finally, ligand exchange releases the desired (*S*)-**3ab** and generates **int-1**.

2.4 Characterization Data of the New BCBs and Products



(1-methyl-1*H*-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone: (1a) Prepared from methyl-3-phenylbicyclo[1.1.0]butane-1-carboxylate (1.88 g, 10.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1a** as a white solid (1.53 g, 64% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.28-7.26 (m, 2H), 7.24-7.16 (m, 3H), 7.07 (s, 1H), 6.85 (s, 1H), 3.63 (s, 2H), 3.60 (s, 3H), 1.90 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.7, 143.4, 133.3, 128.7, 128.2, 127.0, 126.0, 125.7, 40.4, 38.0, 35.7, 32.9 ppm. **HRMS** (ESI) m/z: [M+H]⁺ calcd. for C₁₅H₁₅N₂O: 239.1179; found: 239.1179.



(1-methyl-1*H*-imidazol-2-yl)(3-(*p*-tolyl)bicyclo[1.1.0]butan-1-yl)methanone: (1b) Prepared from methyl 3-(*p*-tolyl)bicyclo[1.1.0]butane-1-carboxylate (0.94 g, 5.00 mmol, 1.0 equiv)

according to the **GP2**. Purification by flash chromatography on silica gel afforded **1b** as a white solid (0.76 g, 60% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.16 (d, *J* = 7.6 Hz, 2H), 7.07 (s, 1H), 7.03 (d, *J* = 7.6 Hz, 2H), 6.85 (s, 1H), 3.61 (s, 5H), 2.27 (s, 3H), 1.88 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.8, 143.4, 136.8, 130.0, 129.0, 128.6, 125.9, 125.7, 41.0, 38.0, 35.7, 32.8, 21.1 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₁₆H₁₇N₂O: 253.1335; found: 253.1334.



1c $C_{15}H_{13}BrN_2O$ M = 317.19 g/mol

(3-(4-bromophenyl)bicyclo[1.1.0]butan-1-yl)(1-methyl-1*H*-imidazol-2-yl)methanone: (1c) Prepared from methyl 3-(4-bromophenyl)bicyclo[1.1.0]butane-1-carboxylate (1.34 g, 5.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1c** as a white solid (0.79 g, 50% yield over 2 steps).

R_f = 0.30 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.33 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.89 (s, 1H), 3.69 (s, 3H), 3.62 (s, 2H), 1.88 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.1, 143.2, 132.7, 131.4, 128.8, 127.6, 126.0, 120.9, 39.4, 38.0, 36.0, 33.0 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₁₅H₁₄BrN₂O: 317.0284; found: 317.0282.



(3-(4-fluorophenyl)bicyclo[1.1.0]butan-1-yl)(1-methyl-1H-imidazol-2-yl)methanone: (1d) Prepared from methyl 3-(4- fluorophenyl)bicyclo[1.1.0]butane-1-carboxylate (1.03 g, 5.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1d** as a white solid (0.64 g, 50% yield over 2 steps).

R_f = 0.30 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.27-7.23 (m, 2H), 7.07 (s, 1H), 6.94-6.88 (m, 3H), 3.68 (s, 3H), 3.61 (s, 2H), 1.89 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.4, 162.1 (d, J = 245 Hz), 143.4, 129.2 (d, J = 3 Hz), 128.9, 127.6 (d, J = 8 Hz), 125.9, 115.3 (d, J = 22 Hz), 39.7, 38.1, 35.9, 32.5 ppm. ¹⁹**F NMR** (376 MHz, CDCl₃) δ -114.956 ppm. **HRMS** (ESI) *m/z*: [M+NH₄]⁺ calcd. for C₁₅H₁₇N₃O: 274.1350; found: 274.1358.



(1-propyl-1H-imidazol-2-yl)(3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.0]butan-1-yl) methanone: (1e) Prepared from methyl 3-(4-(trifluoromethyl)phenyl) bicycle [1.1.0] butane-1carboxylate (1.28 g, 5.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1e** as a white solid (0.71 g, 52% yield over 2 steps).

R_f = 0.36 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.45 (d, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.09 (s, 1H), 6.92 (s, 1H), 4.07 (t, *J* = 7.2 Hz, 2H), 3.68 (s, 2H), 1.95 (s, 2H), 1.19 (q, *J* = 7.2 Hz, 2H), 0.53 (t, *J* = 7.6 Hz, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 184.8, 142.4, 138.1, 128.8 (q, *J* = 30 Hz), 125.7, 125.4, 125.2 (q, *J* = 4 Hz), 122.7, 123.4 (q, *J* = 70 Hz), 50.0, 38.2, 38.1, 33.8, 24.1, 10.5 ppm. ¹⁹**F NMR** (376 MHz, CDCl₃) δ -62.539 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for $C_{18}H_{18}F_{3}N_{2}O$: 335.1366; found: 335.1376.



(1-methyl-1*H*-imidazol-2-yl)(3-(*m*-tolyl)bicyclo[1.1.0]butan-1-yl)methanone: (1f) Prepared from methyl 3-(*m*-tolyl)bicyclo[1.1.0]butane-1-carboxylate (1.01 g, 5.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1f** as a white solid (0.50 g, 40% yield over 2 steps).

R_f = 0.25 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.11-7.04 (m, 4H), 6.98 (d, J = 6.8 Hz, 1H), 6.84 (s, 1H), 3.61 (s, 3H), 3.60 (s, 2H), 2.25 (s, 3H), 1.87 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.8, 143.4, 137.8, 133.1, 128.6, 128.1, 127.8, 126.8, 125.6, 123.0, 40.6, 38.0, 35.7, 32.8, 21.3 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₁₆H₁₇N₂O: 253.1335; found: 253.1334.



(3-(3-chlorophenyl)bicyclo[1.1.0]butan-1-yl)(1-methyl-1*H*-imidazol-2-yl)methanone: (1g) Prepared from methyl 3-(3-chlorophenyl)bicyclo[1.1.0]butane-1-carboxylate (1.11 g, 5.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1g** as a white solid (0.59 g, 43% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.25 (s, 1H), 7.16-7.13 (m, 3H), 7.09 (s, 1H), 6.89 (s, 1H), 3.69 (s, 3H), 3.61 (s, 2H), 1.88 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.1, 143.2, 135.8, 134.2, 129.4, 128.8, 127.0, 126.2, 126.0, 124.2, 38.9, 38.0, 35.9, 33.0 ppm. **HRMS** (ESI) m/z: [M+H]⁺ calcd. for C₁₅H₁₄ClN₂O: 273.0789; found: 273.0787.



(1-methyl-1*H*-imidazol-2-yl)(3-(o-tolyl)bicyclo[1.1.0]butan-1-yl)methanone: (1h) Prepared from methyl methyl 3-(o-tolyl)bicyclo[1.1.0]butane-1-carboxylate (0.61 g, 3.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1h** as a white solid (0.45 g, 59% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.12-7.05 (m, 3H), 7.01-6.96 (m, 2H), 6.93 (s, 1H), 3.85 (s, 3H), 3.35 (s, 2H), 2.44 (s, 3H), 1.94 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 186.8, 143.7, 138.7, 132.3, 130.7, 128.8, 127.1, 126.0, 125.8, 125.6, 41.3, 38.6, 36.1, 30.3, 20.4 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₁₆H₁₇N₂O: 253.1335; found: 253.1335.



(1-methyl-1*H*-imidazol-2-yl)(3-(naphthalen-2-yl)bicyclo[1.1.0]butan-1-yl)methanone: (1i)
Prepared from methyl 3-(naphthalen-2-yl)bicyclo[1.1.0]butane-1-carboxylate (1.19 g, 5.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1i** as a white solid (0.72 g, 50% yield over 2 steps).

R_f = 0.30 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.77 (s, 1H), 7.73 (d, *J* = 8.0 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.44-7.36 (m, 2H), 7.33 (d, *J* = 8.4 Hz, 1H), 7.07 (s, 1H), 6.79 (s, 1H), 3.77 (s, 2H), 3.53 (s, 3H), 1.96 (s, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.4, 143.4, 133.2, 132.4, 131.1, 128.7, 127.8, 127.6, 127.5, 126.2, 125.8, 125.7, 125.6, 123.5, 40.8, 38.2, 35.8, 33.2 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₁₉H₁₇N₂O: 289.1335; found: 289.1331.



(1-ethyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone: (1j) Prepared from methyl-3-phenylbicyclo[1.1.0]butane-1-carboxylate (1.88 g, 10.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1j** as a white solid (1.35 g, 62% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.28-7.24 (m, 2H), 7.20 (t, *J* = 7.2 Hz, 2H), 7.16-7.12 (m, 1H), 7.08 (s, 1H), 6.91 (s, 1H), 4.06 (q, *J* = 7.2 Hz, 2H), 3.63 (s, 2H), 1.91 (s, 2H), 0.94 (t, *J* = 7.2 Hz, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.5, 142.5, 133.3, 128.8, 128.2, 126.9, 125.8, 124.1, 43.3, 40.1, 37.9, 33.0, 16.1 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₁₆H₁₇N₂O: 253.1335; found: 253.1332.



(3-phenylbicyclo[1.1.0]butan-1-yl)(1-propyl-1H-imidazol-2-yl)methanone: (1k) Prepared from methyl-3-phenylbicyclo[1.1.0]butane-1-carboxylate (1.88 g, 10.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded 1k as a white solid (1.47 g, 55% yield over 2 steps).

R_f = 0.30 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.27-7.15 (m, 5H), 7.09 (s, 1H), 6.90 (s, 1H), 4.02 (t, J = 7.2 Hz, 2H), 3.62 (s, 2H), 1.93 (s, 2H), 1.22-1.17 (m, 2H), 0.54 (t, J = 7.2 Hz, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 185.6, 142.6, 133.2, 128.6, 128.3, 126.9, 125.8, 125.0, 49.9, 40.2, 37.9, 33.1, 24.1, 10.7 ppm. **HRMS** (ESI) m/z: [M+H]⁺ calcd. for C₁₇H₁₉N₂O: 267.1492; found: 267.1487.



(1-isopropyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone: (1I) Prepared from methyl-3-phenylbicyclo[1.1.0]butane-1-carboxylate (1.88 g, 10.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1I** as a white solid (1.36 g, 51% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.27-7.15 (m, 5H), 7.11 (s, 1H), 7.08 (s, 1H), 5.03-4.97 (m, 1H), 3.59 (s, 2H), 1.93 (s, 2H), 1.07 (d, J= 6.8 Hz, 6H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 186.1, 142.5, 133.3, 129.1, 128.3, 126.9, 125.8, 119.8, 48.6, 40.1, 38.0, 33.4, 23.3 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₁₇H₁₉N₂O: 267.1492; found: 267.1488.



(1-cyclohexyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone: (1m) Prepared from methyl-3-phenylbicyclo[1.1.0]butane-1-carboxylate (1.88 g, 10.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1m** as a white solid (1.10 g, 52% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.27-7.14 (m, 5H), 7.09 (s, 1H), 7.06 (s, 1H), 4.55-4.49 (m, 1H), 3.57 (s, 2H), 1.93 (s, 2H), 1.67-1.63 (m, 3H), 1.51-1.49 (m, 2H), 1.26-1.15 (m, 4H), 1.09-1.02 (m, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 186.2, 142.6, 133.3, 129.0, 128.2, 126.8, 125.8, 122.2, 56.0, 40.1, 37.9, 34.1, 33.6, 25.5, 25.2 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₂₀H₂₃N₂O: 307.1805; found: 307.1801.



(3-methylbicyclo[1.1.0]butan-1-yl)(1-propyl-1H-imidazol-2-yl)methanone: (1q) Prepared from benzyl 3-methylbicyclo[1.1.0]butane-1-carboxylate (2.02 g, 10.00 mmol, 1.0 equiv) according to the **GP2**. Purification by flash chromatography on silica gel afforded **1q** as a colorless oil (1.02 g, 50% yield over 2 steps).

R_f = 0.40 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.10 (s, 1H), 7.02 (s, 1H), 4.35 (t, *J* = 7.2 Hz, 2H), 2.89 (s, 2H), 1.84-1.74 (m, 2H), 1.57 (s, 3H), 1.53 (s, 2H), 0.91 (t, *J* = 7.2 Hz, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 188.2, 143.2, 128.7, 124.8, 50.3, 41.1, 36.0, 24.7, 23.1, 12.9, 11.0 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for $C_{12}H_{17}N_2O$: 205.1335; found: 205.1333.



(S)-(3-methyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-

yl)methanone: **(3aa)** Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (**1a**, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-methyl-1-phenylmethanimine oxide (**2a**, 32.4 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3aa** as a white solid (64.2 mg, 86% yield).

3aa: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 107-109 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (major) = 10.89 min, tr (minor) = 15.61 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{20} = +66.8$ (*c* = 1.50, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.44 (d, *J* = 6.8 Hz, 2H), 7.39-

7.36 (m, 2H), 7.32-7.28 (m, 1H), 7.20 (s, 1H), 7.15-7.11 (m, 3H), 7.09-7.07 (m, 2H), 6.87 (s, 1H), 4.58 (s, 1H), 3.61 (t, J = 8.6 Hz, 1H), 3.40 (s, 3H), 2.90-2.84 (m, 2H), 2.62 (s, 3H), 2.47 (d, J = 10.4 Hz, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 191.55, 142.6, 141.1, 138.1, 129.1, 128.3, 128.1, 127.9, 127.8, 125.9, 125.9, 81.9, 77.3, 53.8, 49.9, 43.3, 35.1, 33.5 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₂₃H₂₄N₃O₂: 374.1863; found: 374.1856.



(S)-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2yl)methanone: (3ab) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ab as a white solid (72.4 mg, 85% yield).

3ab: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 113-115 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (minor) = 15.00 min, tr (major) = 19.23 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{20} = +79.3$ (c = 0.85, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, J = 7.2 Hz, 2H), 7.30-7.24 (m, 9H), 7.14 (s, 5H), 6.87 (s, 1H), 4.85 (s, 1H), 3.99 (AB, J = 15.2 Hz, 1H), 3.86 (AB, J = 14.8 Hz, 1H), 3.65 (t, J = 9.4 Hz, 1H), 3.41 (s, 3H), 2.93 (d, J = 9.6 Hz, 1H), 2.81 (t, J = 9.2 Hz, 1H), 2.42 (d, J = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.6, 142.6, 141.3, 138.2, 138.1, 129.1, 128.6, 128.2, 128.11, 128.07, 127.9, 127.8, 127.5, 126.6, 125.9, 125.4, 81.7, 74.4, 58.5, 54.1, 49.7, 35.1, 35.0 ppm. HRMS (ESI) m/z: [M+H]⁺ calcd. for C₂₉H₂₈N₃O₂: 450.2166; found: 450.2166.



(S)-(3-isopropyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-

yl)methanone: (**3ac**) Prepared from ((1-methyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone (**1a**, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-isopropyl-1-phenylmethanimine oxide (**2c**, 39.2 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3ac** as a white solid (64.2 mg, 80% yield).

3ac: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 143-145 °C. HPLC analysis (Chiralpak AD-H, *i*PrOH/hexane = 5/95, 1.0 mL/min, 254 nm; tr (minor) = 6.79 min, tr (major) = 8.15 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{20}$ = +37.2 (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.44 (d, *J* = 8.0 Hz, 2H), 7.36 (t, *J* = 7.4 Hz, 2H), 7.30-7.26 (m, 1H), 7.20 (s, 1H), 7.14-7.05 (m, 5H), 6.86 (s, 1H), 4.98 (s, 1H), 3.57 (t, *J* = 9.4 Hz, 1H), 3.38 (s, 3H), 2.94-2.90 (m, 1H), 2.87 (d, *J* = 9.6 Hz, 1H), 2.74 (t, *J* = 9.0 Hz, 1H), 2.37 (d, *J* = 10.0 Hz, 1H), 1.21 (d, *J* = 6.8 Hz, 3H), 1.14 (d, *J* = 6.4 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 192.1, 142.78, 142.0, 138.8, 129.0, 128.2, 127.9, 127.74, 127.71, 127.5, 125.7, 125.4, 80.8, 70.1, 53.9, 51.5, 49.3, 35.1, 34.4, 21.2, 14.0 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₅H₂₆N₃O₂: 402.2176; found: 402.2176.



(S)-(1-methyl-1H-imidazol-2-yl)(1,3,4-triphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)methanone: (3ad) Prepared from ((1-methyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1yl)methanone (**1a**, 47.6 mg, 0.20 mmol) and (*Z*)-*N*,1-diphenylmethanimine oxide (**2d**, 47.3 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3ad** as colorless oil (78.4 mg, 90% yield).

3ad: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, ⁷PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (minor) = 13.10 min, tr (major) = 20.54 min) gave the isomeric composition of the product: 94% ee. $[\alpha]_{D}^{20} = +66.8$ (*c* = 1.38, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.49 (d, *J* = 7.6 Hz, 2H), 7.41 (t, *J* = 7.6 Hz, 2H), 7.36-7.31 (m, 1H), 7.18-7.14 (m, 8H), 7.06 (d, *J* = 8.0 Hz, 2H), 6.97 (s, 1H), 6.86 (t, *J* = 7.4 Hz, 1H), 6.02 (s, 1H), 3.71 (s, 3H), 3.24-3.16 (m, 2H), 2.73 (d, *J* = 9.6 Hz, 1H), 2.65 (d, *J* = 9.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 190.8, 149.8, 142.1, 140.5, 138.6, 129.4, 128.5, 128.4, 128.1, 127.6, 127.5, 126.4, 125.9, 121.6, 117.0, 83.6, 71.1, 54.1, 45.4, 35.7, 35.7 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₈H₂₆N₃O₂: 436.2020; found: 436.2011.



(*S*)-(3-benzyl-4-(2-methoxyphenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ae) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(2-methoxyphenyl)methanimine oxide (2e, 57.9 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ae as a white solid (89.2 mg, 93% yield).

3ae: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 161-163 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 8.97 min, tr (major) = 11.54 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_D^{20}$ =

+96.0 (*c* = 2.00, CHCl₃). ¹**H NMR** (400 MHz, CDCl₃): δ 7.65 (d, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 7.6 Hz, 2H), 7.32-7.21 (m, 7H), 7.19-7.09 (m, 3H), 6.88 (t, *J* = 7.6 Hz, 1H), 6.81 (s, 1H), 6.60 (d, *J* = 8.4 Hz, 1H), 5.34 (s, 1H), 3.94 (AB, *J* = 14.8 Hz, 1H), 3.90 (AB, *J* = 14.8 Hz, 1H), 3.72 (t, *J* = 9.2 Hz, 1H), 3.47 (s, 3H), 3.40 (s, 3H), 2.99 (d, *J* = 9.6 Hz, 1H), 2.90 (t, *J* = 9.2 Hz, 1H), 2.46 (d, *J* = 10.0 Hz, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 192.3, 156.8, 142.7, 141.5, 138.7, 129.2, 128.9, 128.8, 128.4, 128.1, 127.7, 127.4, 126.4, 126.1, 125.43, 125.35, 120.6, 109.9, 81.7, 65.8, 58.4, 55.2, 53.9, 50.0, 35.8, 35.0 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₃: 480.2282; found: 480.2270.



(S)-(3-benzyl-1-phenyl-4-(o-tolyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)(3-yl)methanone: (3af) Prepared from ((1-methyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-N-benzyl-1-(o-tolyl)methanimine oxide (2f, 54.0 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3af as a white solid (66.8 mg, 72% yield).

3af: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 175-177 °C. HPLC analysis (Chiralpak IC, /PrOH/hexane = 15/85, 0.8 mL/min, 254 nm; tr (major) = 8.86 min, tr (minor) = 9.20 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +116.9 (*c* = 1.50, CHCl₃). ¹**H NMR** (400 MHz, CDCl₃): δ 7.66 (d, *J* = 8.0 Hz, 1H), 7.34 (d, *J* = 7.2 Hz, 2H), 7.28-7.20 (m, 8H), 7.15-7.10 (m, 2H), 7.03 (t, *J* = 7.4 Hz, 1H), 6.90 (d, *J* = 7.6 Hz, 1H), 6.82 (s, 1H), 5.06 (s, 1H), 3.90 (s, 1H), 3.92 (AB, *J* = 14.4 Hz, 1H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.79 (t, *J* = 9.2 Hz, 1H), 3.37 (s, 3H), 3.02 (d, *J* = 9.6 Hz, 1H), 2.86 (t, *J* = 9.2 Hz, 1H), 2.50 (d, *J* = 10.0 Hz, 1H), 2.05 (s, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 192.1, 142.7, 141.3, 138.5, 136.8, 135.9, 130.0, 128.9, 128.4, 128.2, 128.1, 127.8,

127.7, 127.5, 126.5, 126.2, 126.0, 125.4, 81.8, 69.3, 57.8, 54.2, 50.5, 36.1, 34.9, 19.4 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2324.



(S)-(3-benzyl-4-(3-methoxyphenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ag) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-N-benzyl-1-(3-methoxyphenyl)methanimine oxide (2g, 57.9 mg, 0.24 mmol) according to the GP1 at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ag as colorless oil (57.5 mg, 60% yield).

3ag: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, ⁷PrOH/hexane = 15/85, 0.8 mL/min, 254 nm; tr (minor) = 16.40 min, tr (major) = 17.12 min) gave the isomeric composition of the product: 98% ee. [α]_D²⁰ = +63.7 (*c* = 1.38, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.38 (d, *J* = 8.4 Hz, 2H), 7.30-7.27 (m, 6H), 7.23-7.20 (m, 3H), 7.06 (t, *J* = 8.0 Hz, 1H), 6.91 (s, 1H), 6.76-6.67 (m, 3H), 4.83 (s, 1H), 4.01 (AB, *J* = 14.8 Hz, 1H), 3.86 (AB, *J* = 14.8 Hz, 1H), 3.65 (s, 3H), 3.62 (t, *J* = 9.6 Hz, 1H), 3.49 (s, 3H), 2.92 (d, *J* = 10.0 Hz, 1H), 2.79 (t, *J* = 9.2 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.5, 159.3, 142.8, 141.3, 139.6, 138.2, 129.2, 129.1, 128.7, 128.2, 127.9, 127.5, 126.6, 125.9, 125.4, 120.0, 114.2, 112.8, 81.7, 74.3, 58.7, 55.1, 54.1, 49.7, 35.2, 35.0 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₃: 480.2282; found: 480.2271.



(*S*)-(3-benzyl-1-phenyl-4-(*m*-tolyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2yl)methanone: (3ah) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-N-benzyl-1-(m-tolyl)methanimine oxide (2h, 54.0 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3ah** as a white solid (76.0 mg, 82% yield).

3ah: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 111-113 °C. HPLC analysis (Chiralcel IC, /PrOH/hexane = 10/90, 0.8 mL/min, 254 nm; tr (minor) = 8.18 min, tr (major) = 8.61 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +97.5 (*c* = 1.88, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.6 Hz, 2H), 7.30-7.26 (m, 6H), 7.24-7.19 (m, 3H), 7.04-7.01 (m, 1H), 6.97-6.93 (m, 2H), 6.87 (s, 2H), 4.78 (s, 1H), 4.00 (AB, *J* = 14.8 Hz, 1H), 3.84 (AB, *J* = 14.8 Hz, 1H), 3.64 (t, *J* = 9.4 Hz, 1H), 3.40 (s, 3H), 2.93 (d, *J* = 9.6 Hz, 1H), 2.80 (t, *J* = 9.2 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H), 2.19 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.7, 142.8, 141.4, 138.2, 138.0, 137.6, 129.0, 128.8, 128.6, 128.5, 128.1, 128.0, 127.8, 127.5, 126.6, 125.7, 125.4, 124.8, 81.7, 74.3, 58.6, 54.0, 49.7, 35.0, 34.9, 21.23 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2323.



(S)-(3-benzyl-4-(3-(tert-butyl)phenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ai) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-N-benzyl-1-(3-(tert-butyl)phenyl)methanimine oxide (2i, 64.2 mg, 0.24 mmol) according to the GP1 at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ai as colorless oil (87.0 mg, 86% yield).

3ai: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 11.76 min, tr (major) = 18.65 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +30.9 (*c* = 2.13, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.2 Hz, 2H), 7.31-7.25 (m, 6H), 7.23-7.18 (m, 4H), 7.16-7.11 (m, 2H), 6.98 (s, 1H), 6.84 (s, 1H), 4.85 (s, 1H), 4.02 (AB, *J* = 14.8 Hz, 1H), 3.86 (AB, *J* = 14.8 Hz, 1H), 3.66 (t, *J* = 9.4 Hz, 1H), 3.41 (s, 3H), 2.91 (d, *J* = 9.6 Hz, 1H), 2.81 (t, *J* = 9.2 Hz, 1H), 2.41 (d, *J* = 10.4 Hz, 1H), 1.13 (s, 9H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.5, 150.7, 142.7, 141.4, 138.3, 137.6, 129.0, 128.6, 128.12, 128.07, 127.8, 127.5, 126.6, 125.9, 125.5, 125.4, 124.9, 124.5, 81.7, 74.7, 58.6, 54.1, 49.8, 35.2, 35.0, 34.5, 31.2 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₃H₃₆N₃O₂: 506.2802; found: 506.2792.



(*S*)-(3-benzyl-4-(3-bromophenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3aj) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(3-bromophenyl)methanimine oxide (2j, 69.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ai as a white solid (81.4 mg, 77% yield). **3aj**: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 70-72 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 9.82 min, tr (minor) = 13.10 min) gave the isomeric composition of the product: 99.6% ee. [α]_D²⁰ = +47.1 (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.36 (d, *J* = 7.6 Hz, 2H), 7.30-7.23 (m, 11H), 7.07-7.03 (m, 2H), 6.95 (s, 1H), 4.83 (s, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.87 (AB, *J* = 14.8 Hz, 1H), 3.56 (d, *J* = 9.4 Hz, 1H), 3.52 (s, 3H), 2.91 (d, *J* = 9.6 Hz, 1H), 2.78 (t, *J* = 9.4 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.1, 142.4, 141.1, 140.5, 137.7, 131.2, 131.1, 129.9, 129.3, 128.7, 128.2, 127.9, 127.6, 126.8, 126.4, 126.3, 125.4, 122.0, 81.7, 73.7, 58.9, 54.1, 49.5, 35.2, 34.7 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇BrN₃O₂: 528.1281; found: 528.1271.



(*S*)-(3-benzyl-4-(3-fluorophenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ak) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(3-fluorophenyl)methanimine oxide (2k, 55.0 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ak as colorless oil (68.2 mg, 73% yield).

3ak: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 10.03 min, tr (minor) = 10.55 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +86.1 (*c* = 1.50, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.36 (d, *J* = 7.6 Hz, 2H), 7.31-7.22 (m, 9H), 7.13-7.08 (m, 1H), 6.94-6.84 (m, 4H), 4.89 (s, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.87 (AB, *J* = 14.8 Hz, 1H), 3.59 (t, *J* = 9.4 Hz, 1H), 3.53 (s, 3H), 2.90 (d, *J* = 10.0 Hz, 1H), 2.78 (t, *J* = 9.2 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.2, 162.5 (d, J = 244 Hz), 142.4, 141.1, 140.8 (d, J = 7 Hz), 137.9, 129.6 (d, J = 8 Hz), 129.3, 128.7, 128.2, 127.9, 127.6, 126.8, 126.2, 125.4, 123.5 (d, J = 3 Hz), 115.0 (d, J = 18 Hz), 114.8 (d, J = 19 Hz), 81.7, 73.7 (d, J = 2 Hz), 58.8, 54.1, 49.6, 35.3, 34.9 ppm. ¹⁹**F** NMR (376 MHz, CDCl₃): δ -112.755 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇FN₃O₂: 468.2072; found: 468.2082.



(S)-(3-benzyl-4-(4-methoxyphenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3al) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(4-methoxyphenyl)methanimine oxide (2l, 57.9 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3al as a white solid (76.7 mg, 80% yield).

3aI: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 145-147 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 14.42 min, tr (minor) = 16.83 min) gave the isomeric composition of the product: 97% ee. $[\alpha]_{D}^{20} = +52.0$ (*c* = 1.88, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.6 Hz, 2H), 7.29-7.20 (m, 9H), 7.07 (d, *J* = 8.0 Hz, 2H), 6.89 (s, 1H), 6.68 (d, *J* = 8.0 Hz, 2H), 4.82 (s, 1H), 3.96 (AB, *J* = 15.2 Hz, 1H), 3.83 (AB, *J* = 15.2 Hz, 1H), 3.72 (s, 3H), 3.63 (t, *J* = 9.4 Hz, 1H), 3.49 (s, 3H), 2.91 (d, *J* = 9.6 Hz, 1H), 2.78 (t, *J* = 9.2 Hz, 1H), 2.40 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.8, 159.2, 142.6, 141.4, 138.3, 130.2, 129.1, 129.0, 128.6, 128.1, 127.8, 127.5, 126.6, 125.9, 125.4, 113.5, 81.6, 73.7, 58.3, 55.1, 54.0, 49.7, 35.3, 34.9 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₃: 480.2282; found: 480.2272.



(S)-(3-benzyl-1-phenyl-4-(p-tolyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)(3-yl)methanone: (3am) Prepared from ((1-methyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-N-benzyl-1-(p-tolyl)methanimine oxide (2m, 54.0 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3am as a white solid (69.5 mg, 75% yield).

3am: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 91-93 °C. HPLC analysis (Chiralpak AD-H, 'PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 10.45 min, tr (minor) = 12.95 min) gave the isomeric composition of the product: 98% ee. [α]_D²⁰ = +75.4 (*c* = 1.50, CHCl₃). ¹**H NMR** (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.2 Hz, 2H), 7.29-7.20 (m, 9H), 7.02 (d, *J* = 8.0 Hz, 2H), 6.94 (d, *J* = 7.6 Hz, 2H), 6.89 (s, 1H), 4.82 (s, 1H), 4.00 (AB, *J* = 14.8 Hz, 1H), 3.83 (AB, *J* = 14.8 Hz, 1H), 3.64 (t, *J* = 9.2 Hz, 1H), 3.44 (s, 3H), 2.92 (d, *J* = 9.6 Hz, 1H), 2.79 (t, *J* = 9.2 Hz, 1H), 2.40 (d, *J* = 10.0 Hz, 1H), 2.23 (s, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 191.8, 142.7, 141.4, 138.3, 137.7, 135.1, 129.1, 128.8, 128.6, 128.1, 127.8, 127.7, 127.5, 126.6, 125.9, 125.4, 81.6, 74.0, 58.4, 54.1, 49.7, 35.2, 35.0, 21.1 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2325.



(S)-(4-([1,1'-biphenyl]-4-yl)-3-benzyl-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3an) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-1-([1,1'biphenyl]-4-yl)-N-benzylmethanimine oxide (2n, 70.0 mg, 0.24 mmol) according to the GP1 at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3an as a white solid (98.8 mg, 94% yield).

3an: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 125-127 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 15.70 min, tr (minor) = 18.52 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{20}$ = +4.5 (*c* = 2.48, CHCl₃). ¹**H NMR** (400 MHz, CDCl₃): δ 7.50 (d, *J* = 7.6 Hz, 2H), 7.42-7.37 (m, 6H), 7.33-7.27 (m, 7H), 7.24–7.20 (m, 5H), 6.88 (s, 1H), 4.90 (s, 1H), 4.05 (AB, *J* = 14.8 Hz, 1H), 3.89 (AB, *J* = 15.2 Hz, 1H), 3.69 (t, *J* = 9.4 Hz, 1H), 3.43 (s, 3H), 2.94 (d, *J* = 9.6 Hz, 1H), 2.82 (t, *J* = 9.0 Hz, 1H), 2.45 (d, *J* = 10.0 Hz, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 191.6, 142.6, 141.3, 140.8, 140.5, 138.1, 137.2, 129.2, 128.8, 128.7, 128.3, 128.2, 127.9, 127.6, 127.3, 126.9, 126.7, 126.6, 125.9, 125.4, 81.7, 74.1, 58.6, 54.1, 49.8, 35.2, 35.0 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₅H₃₂N₃O₂: 526.2489; found: 526.2475.


(S)-(3-benzyl-4-(4-bromophenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ao) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(4-bromophenyl)methanimine oxide (2o, 69.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ao as a white solid (87.7mg, 83% yield).

3ao: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 125-127 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 12.33 min, tr (minor) = 13.94 min) gave the isomeric composition of the product: 99.6% ee. $[\alpha]_{D}^{20} = +26.9 (c = 2.10, CHCl_{3})$. ¹H NMR (400 MHz, CDCl_{3}): δ 7.34 (d, J = 7.6 Hz, 2H), 7.30-7.21 (m, 11H), 7.05 (d, J = 8.0 Hz, 2H), 6.93 (s, 1H), 4.88 (s, 1H), 3.95 (AB, J = 14.8 Hz, 1H), 3.85 (AB, J = 14.8 Hz, 1H), 3.60 (t, J = 9.8 Hz, 1H), 3.55 (s, 3H), 2.89 (d, J = 9.6 Hz, 1H), 2.76 (t, J = 9.2 Hz, 1H), 2.41 (d, J = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl_{3}): δ 191.2, 142.3, 141.1, 137.8, 137.2, 131.3, 129.6, 129.3, 128.7, 128.2, 127.9, 127.6, 126.8, 126.2, 125.4, 122.0, 81.7, 73.6, 58.6, 54.0, 49.7, 35.4, 34.9 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇BrN₃O₂: 528.1281; found: 528.1270.



(S)-(3-benzyl-4-(4-chlorophenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-

imidazol-2-yl)methanone: (**3ap**) Prepared from ((1-methyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone (**1a**, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(4-chlorophenyl)methanimine oxide (**2p**, 58.8 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3ap** as a white solid (77.4 mg, 80% yield).

3ap: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 107-109 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 12.08 min, tr (minor) = 14.57 min) gave the isomeric composition of the product: 98% ee. $[\alpha]_{D}^{20}$ = +44.8 (*c* = 1.88, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.34 (d, *J* = 7.6 Hz, 2H), 7.30-7.20 (m, 9H), 7.13-7.19 (m, 4H), 6.92 (s, 1H), 4.89 (s, 1H), 3.95 (AB, *J* = 14.8 Hz, 1H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.60 (t, *J* = 9.4 Hz, 1H), 3.54 (s, 3H), 2.89 (d, *J* = 9.6 Hz, 1H), 2.77 (t, *J* = 9.2 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.2, 142.3, 141.1, 137.9, 136.7, 133.8, 129.29, 129.26, 128.6, 128.3, 128.2, 127.9, 127.6, 126.7, 126.2, 125.4, 81.7, 73.6, 58.6, 54.0, 50.0, 35.4, 34.9 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇ClN₃O₂: 484.1786; found: 484.1778.



(*S*)-(3-benzyl-4-(4-fluorophenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3aq) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(4-fluorophenyl)methanimine oxide (2q, 55.0 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3aq as colorless oil (77.6 mg, 83% yield). **3aq**: $\mathbf{R}_r = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 11.00 min, tr (minor) = 14.11 min) gave the isomeric composition of the product: 98% ee. $[\alpha]_D^{20} = +68.1$ (*c* = 1.00, CHCl₃). ¹**H NMR** (400 MHz, CDCl₃): δ 7.35 (d, *J* = 8.8 Hz, 2H), 7.30-7.20 (m, 9H), 7.16-7.13 (m, 2H), 6.90 (s, 1H), 6.84 (t, *J* = 8.8 Hz, 2H), 4.89 (s, 1H), 3.96 (AB, *J* = 14.8 Hz, 1H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.61 (t, *J* = 9.4 Hz, 1H), 3.52 (s, 3H), 2.90 (d, *J* = 9.6 Hz, 1H), 2.78 (t, *J* = 9.0 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 191.4, 162.4 (d, *J* = 246 Hz), 142.4, 141.2, 138.0, 134.0 (d, *J* = 3 Hz), 129.6 (d, *J* = 8 Hz), 129.2, 128.6, 128.2, 127.9, 127.6, 126.7, 126.1, 125.4, 115.0 (d, *J* = 21 Hz), 114.9, 81.7, 73.5, 58.5, 54.0, 49.7, 35.3, 34.9 ppm. ¹⁹**F NMR** (376 MHz, CDCl₃): δ -113.657ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇FN₃O₂: 468.2082; found: 468.2073.



(S)-(3-benzyl-4-(4-iodophenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ar) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-N-benzyl-1-(4-iodophenyl)methanimine oxide (2r, 80.9 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ar as a white solid (92.1 mg, 80% yield).

3ar: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 155-157 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 12.19 min, tr (minor) = 13.19 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +13.5 (*c* = 2.25, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (d, *J* = 7.6 Hz, 2H), 7.34 (d, *J* = 7.6

Hz, 2H), 7.29-7.23 (m, 8H), 7.20 (s, 1H), 6.91 (d, J = 8.4 Hz, 3H), 4.86 (s, 1H), 3.95 (AB, J = 14.8 Hz, 1H), 3.85 (AB, J = 14.8 Hz, 1H), 3.59 (t, J = 9.4 Hz, 1H), 3.54 (s, 3H), 2.89 (d, J = 10.0 Hz, 1H), 2.76 (t, J = 9.2 Hz, 1H), 2.41 (d, J = 10.4 Hz, 1H) ppm. ¹³**C NMR** (100 MHz, CDCI₃): δ 191.2, 142.3, 141.1, 137.9, 137.8, 137.3, 129.8, 129.3, 128.6, 128.2, 127.9, 127.6, 126.7, 126.2, 125.4, 93.8, 81.7, 73.7, 58.6, 54.0, 49.6, 35.4, 34.9 ppm. **HRMS** (ESI) m/z: [M+H]⁺ calcd. for C₂₉H₂₇IN₃O₂: 576.1142; found: 576.1133.



(S)-(3-benzyl-4-(4-ethynylphenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3as) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(4-ethynylphenyl)methanimine oxide (2s, 56.5 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3as as a white solid (66.3 mg, 70% yield).

3as: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 93-95 °C. HPLC analysis (Chiralpak IC, /PrOH/hexane = 5/95, 0.8 mL/min, 254 nm; tr (minor) = 10.68 min, tr (major) = 11.58 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +19.2 (*c* = 1.50, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.34 (d, *J* = 7.6 Hz, 2H), 7.30-7.21 (m, 11H), 7.12 (d, *J* = 7.6 Hz, 2H), 6.90 (s, 1H), 4.89 (s, 1H), 3.94 (AB, *J* = 14.8 Hz, 1H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.61 (t, *J* = 9.4 Hz, 1H), 3.50 (s, 3H), 3.03 (s, 1H), 2.90 (d, *J* = 9.6 Hz, 1H), 2.78 (t, *J* = 9.2 Hz, 1H), 2.42 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.2, 142.4, 141.2, 139.0, 137.9, 131.9, 129.2, 128.7, 128.2, 128.0, 127.9, 127.6, 126.7, 126.1, 125.4, 121.8, 83.3, 81.7, 77.5, 74.0, 58.7, 54.1, 49.7, 35.3, 35.0 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₁H₂₈N₃O₂: 474.2176; found: 474.2169.



(S)-(3-benzyl-4-(3,4-dimethoxyphenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)methanone: (3at) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(3,4-dimethoxyphenyl)methanimine oxide (2t, 65.1 mg, 0.24 mmol) according to the GP1 at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3at as a white solid (87.7 mg, 86% yield).

3at: $\mathbf{R}_f = 0.3$ (petroleum ether/EtOAc = 1/1). Mp: 159-161 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 13.12 min, tr (minor) = 16.81 min) gave the isomeric composition of the product: 98% ee. $[\alpha]_D^{20} = +51.2$ (*c* = 2.10, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.38 (d, *J* = 7.6 Hz, 2H), 7.30-7.22 (m, 9H), 6.91 (s, 1H), 6.85 (d, *J* = 8.4 Hz, 1H), 6.69 (d, *J* = 8.4 Hz, 1H), 6.58 (s, 1H), 4.83 (s, 1H), 4.02 (AB, *J* = 14.8 Hz, 1H), 3.86 (AB, *J* = 14.8 Hz, 1H), 3.80 (s, 3H), 3.66 (s, 3H), 3.62 (t, *J* = 9.4 Hz, 1H), 3.53 (s, 3H), 2.90 (d, *J* = 9.6 Hz, 1H), 2.77 (t, *J* = 9.2 Hz, 1H), 2.40 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.5, 148.5, 148.2, 142.7, 141.3, 138.3, 130.6, 129.0, 128.6, 128.1, 127.8, 127.5, 126.6, 125.9, 125.4, 119.8, 111.1, 110.9, 81.6, 73.9, 58.5, 55.7, 55.6, 54.1, 49.7, 35.4, 34.9 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₁H₃₂N₃O₄: 510.2387; found: 510.2378.



(S)-(3-benzyl-4-(3,5-dimethylphenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3au) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-N-benzyl-1-(3,5-dimethylphenyl)methanimine oxide (2u, 57.4 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3au as colorless oil (82.1 mg, 86% yield).

3au: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (major) = 7.52 min, tr (minor) = 9.74 min) gave the isomeric composition of the product: 97% ee. $[\alpha]_{D}^{20} = +85.3$ (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.38 (d, *J* = 7.2 Hz, 2H), 7.30-7.21 (m, 9H), 6.88 (s, 1H), 6.78 (s, 1H), 6.69 (s, 2H), 4.72 (s, 1H), 4.01 (AB, *J* = 14.8 Hz, 1H), 3.83 (AB, *J* = 14.8 Hz, 1H), 3.62 (t, *J* = 9.4 Hz, 1H), 3.40 (s, 3H), 2.93 (d, *J* = 9.6 Hz, 1H), 2.79 (t, *J* = 9.2 Hz, 1H), 2.40 (d, *J* = 10.0 Hz, 1H), 2.15 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.8, 143.0, 141.4, 138.3, 137.9, 137.4, 129.6, 129.0, 128.7, 128.1, 127.8, 127.5, 126.6, 125.6, 125.5, 125.4, 81.7, 74.3, 58.6, 54.0, 49.6, 34.9, 34.8, 21.2 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₁H₃₂N₃O₂: 478.2489; found: 478.2478.



(*S*)-(3-benzyl-4-(naphthalen-1-yl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3av) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-*N*-benzyl-1-(naphthalen-1-yl)methanimine oxide (2v, 62.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3av as a white solid (86.9 mg, 87% yield). **3av**: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 180-182 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 11.64 min, tr (minor) = 16.06 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_D^{20}$ = +165.5 (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.10 (d, *J* = 7.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 1H), 7.70 (t, *J* = 7.8 Hz, 2H), 7.46 (t, *J* = 8.0 Hz, 1H), 7.36-7.28 (m, 7H), 7.26-7.18 (m, 5H), 7.04 (s, 1H), 6.50 (s, 1H), 5.60 (s, 1H), 3.98-3.82 (m, 3H), 3.09 (d, *J* = 10.0 Hz, 1H), 2.99 (t, *J* = 9.4 Hz, 1H), 2.83 (s, 3H), 2.45 (d, *J* = 10.4 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.7, 142.5, 141.3, 138.0, 133.6, 133.4, 130.9, 128.8, 128.7, 128.4, 128.24, 128.17, 127.8, 127.6, 126.6, 125.8, 125.7, 125.5, 125.1, 124.9, 123.0, 81.7, 67.4, 58.6, 54.7, 49.9, 35.9, 34.3 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₃H₃₀N₃O₂: 500.2333; found: 500.2323.



(S)-(3-benzyl-4-(naphthalen-2-yl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3aw) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (Z)-N-benzyl-1-(naphthalen-2-yl)methanimine oxide (2w, 62.7 mg, 0.24 mmol) according to the GP1 at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3aw as a white solid (82.9 mg, 83% yield).

3aw: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 173-175 °C. HPLC analysis (Chiralpak IC, ^{*i*}PrOH/hexane = 10/90, 0.8 mL/min, 254 nm; tr (minor) = 9.06 min, tr (major) = 9.91 min) gave the isomeric composition of the product: 98% ee. $[\alpha]_D^{20} = +51.8$ (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.75-7.72 (m, 1H), 7.67 (d, *J* = 8.4 Hz, 1H), 7.63-7.61 (m, 1H), 7.45-7.34 (m, 6H), 7.32-7.18 (m, 9H), 6.84 (s, 1H), 5.03

(s, 1H), 4.03 (AB, J = 14.8 Hz, 1H), 3.89 (AB, J = 14.8 Hz, 1H), 3.74 (t, J = 9.4 Hz, 1H), 3.19 (s, 3H), 2.96 (d, J = 10.0 Hz, 1H), 2.85 (t, J = 9.0 Hz, 1H), 2.47 (d, J = 10.0 Hz, 1H) ppm. ¹³**C** NMR (100 MHz, CDCl₃): δ 191.5, 142.7, 141.3, 138.1, 135.7, 133.2, 133.0, 129.2, 128.7, 128.2, 127.94, 127.85, 127.6, 127.5, 127.4, 126.7, 126.0, 125.9, 125.44, 125.35, 81.8, 74.4, 58.7, 54.2, 49.8, 35.1, 35.0 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₃H₃₀N₃O₂: 500.2333; found: 500.2323.



(*R*)-(3-benzyl-4-(1H-indol-2-yl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ax) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(1H-indol-2-yl)methanimine oxide (2x, 60.1 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ax as a white solid (30.3 mg, 31% yield).

3ax: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 188-190 °C. HPLC analysis (Chiralpak AD-H, PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 14.81 min, tr (major) = 28.58 min) gave the isomeric composition of the product: 95% ee. $[\alpha]_{D}^{20} =$ +18.1 (*c* = 0.75, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 8.45 (s, 1H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.37-7.22 (m, 12H), 7.10 (t, *J* = 7.6 Hz, 1H), 7.01 (t, *J* = 7.6 Hz, 1H), 6.92 (s, 1H), 5.88 (s, 1H), 5.24 (s, 1H), 4.10 (AB, *J* = 14.8 Hz, 1H), 3.96 (AB, *J* = 14.8 Hz, 1H), 3.57 (t, *J* = 9.4 Hz, 1H), 3.51 (s, 3H), 2.86 (d, *J* = 9.6 Hz, 1H), 2.75 (t, *J* = 9.2 Hz, 1H), 2.50 (d, *J* = 10.4 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 190.5, 142.4, 141.0, 137.5, 135.8, 134.9, 129.2, 129.0, 128.3, 128.0, 127.7, 126.9, 126.3, 125.4, 121.9, 120.2,

119.7, 111.1, 101.4, 81.8, 68.1, 59.2, 53.4, 49.0, 35.5, 34.8 ppm. **HRMS** (ESI) m/z: [M+H]⁺ calcd. for C₃₁H₂₉N₄O₂: 489.2275; found: 489.2275.



(*R*)-(3-benzyl-4-(furan-2-yl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)methanone: (3ay) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(furan-2-yl)methanimine oxide (2y, 48.3 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ay as a white solid (52.7 mg, 60% yield).

3ay: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 107-109 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 14.63 min, tr (minor) = 19.42 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{20}$ = +56.4 (*c* = 1.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.39 (d, *J* = 7.6 Hz, 2H), 7.32-7.21 (m, 10H), 7.05 (s, 1H), 6.97 (s, 1H), 6.18 (s, 1H), 5.01 (s, 1H), 4.11 (AB, *J* = 14.8 Hz, 1H), 3.89 (AB, *J* = 14.8 Hz, 1H), 3.73 (s, 3H), 3.50 (t, *J* = 9.4 Hz, 1H), 2.83 (d, *J* = 9.6 Hz, 1H), 2.71 (t, *J* = 9.2 Hz, 1H), 2.38 (d, *J* = 10.4 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.3, 143.0, 142.3, 141.3, 140.4, 138.2, 129.2, 128.6, 128.2, 127.9, 127.5, 126.7, 126.2, 125.4, 122.5, 109.1, 81.7, 66.2, 58.6, 53.4, 49.1, 35.6, 34.4 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₇H₂₆N₃O₃: 440.1969; found: 440.1965.



(*R*)-(3-benzyl-1-phenyl-4-(thiophen-2-yl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3az) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-(thiophen-2-yl)methanimine oxide (2z, 52.2 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3az as a white solid (72.9 mg, 80% yield).

3az: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 91-93 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 12.91 min, tr (major) = 14.54 min) gave the isomeric composition of the product: 99.7% ee. [α]_D²⁰ = +71.2 (*c* = 1.75, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.42 (d, *J* = 7.6 Hz, 2H), 7.32-7.21 (m, 9H), 7.17 (d, *J* = 5.2 Hz, 1H), 6.97 (s, 1H), 6.74 (t, *J* = 4.2 Hz, 1H), 6.35 (s, 1H), 5.37 (s, 1H), 4.12 (AB, *J* = 14.8 Hz, 1H), 3.89 (AB, *J* = 14.8 Hz, 1H), 3.64 (s, 3H), 3.59 (t, *J* = 9.4 Hz, 1H), 2.87 (d, *J* = 9.6 Hz, 1H), 2.76 (t, *J* = 9.2 Hz, 1H), 2.37 (d, *J* = 10.4 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 190.7, 142.4, 141.14, 141.09, 138.0, 129.2, 128.7, 128.2, 127.9, 127.6, 126.7, 126.2, 125.8, 125.7, 125.4, 124.9, 81.7, 69.8, 58.7, 54.1, 48.6, 35.5, 34.1 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₇H₂₆N₃O₂S: 456.1740; found: 456.1735.



 $C_{29}H_{33}N_3O_2$ M = 455.60 g/mol (*S*)-(3-benzyl-4-cyclohexyl-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)methanone: (3aaa) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1a, 47.6 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-cyclohexylmethanimine oxide (2aa, 52.2 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3aaa as a white solid (54.7 mg, 60% yield).

3aaa: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 131-133 °C. HPLC analysis (Chiralpak AD-H, 'PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (major) = 7.40 min, tr (minor) = 8.31 min) gave the isomeric composition of the product: 70% ee. $[\alpha]_{D}^{20} = +67.1$ (*c* = 1.38, CHCl₃). ¹H NMR (600 MHz, CDCl₃): δ 7.49 (d, *J* = 7.2 Hz, 2H), 7.33 (t, *J* = 5.0 Hz, 2H), 7.24 (s, 5H), 7.20-7.19 (m, 2H), 7.01 (s, 1H), 4.44 (AB, *J* = 14.8 Hz, 1H), 4.27 (AB, *J* = 14.8 Hz, 1H), 4.12 (s, 1H), 4.00 (s, 3H), 3.07 (t, *J* = 9.4 Hz, 1H), 2.78 (t, *J* = 9.4 Hz, 1H), 2.60 (d, *J* = 10.8 Hz, 1H), 2.49 (d, *J* = 10.2 Hz, 1H), 1.84 (d, *J* = 12.6 Hz, 1H), 1.65-1.54 (m, 5H), 1.17-1.11 (m, 1H), 1.07-0.96 (m, 3H), 0.78-0.74 (m, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 192.9, 142.1, 141.4, 139.0, 129.2, 128.8, 128.1, 128.0, 127.4, 126.7, 126.3, 125.4, 81.4, 73.2, 63.2, 52.4, 48.5, 43.0, 36.6, 36.2, 29.9, 29.3, 27.2, 27.1, 26.5 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₃₄N₃O₂: 456.2646; found: 456.2638.



(*S*,*E*)-(3-benzyl-1-phenyl-4-styryl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2yl)methanone: (**3abb**) Prepared from ((1-methyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (**1a**, 47.6 mg, 0.20 mmol) and (1*Z*,2*E*)-*N*benzyl-3-phenylprop-2-en-1-imine oxide (**2bb**, 57.0 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3abb** as a white solid (73.2 mg, 77% yield).

3abb: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 141-143 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (minor) = 13.50 min, tr (major) = 14.24 min) gave the isomeric composition of the product: 97% ee. $[\alpha]_{D}^{20}$ = +12.3 (*c* = 1.75, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.44 (d, *J* = 7.6 Hz, 2H), 7.30-7.27 (m, 6H), 7.22-7.18 (m, 6H), 7.15-7.13 (m, 2H), 6.90 (s, 1H), 6.19-6.08 (m, 2H), 4.50 (d, *J* = 8.2 Hz, 1H), 4.28 (AB, *J* = 14.8 Hz, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.69 (s, 3H), 3.50 (t, *J* = 9.2 Hz, 1H), 2.83 (d, *J* = 9.6 Hz, 1H), 2.71 (t, *J* = 9.0 Hz, 1H), 2.39 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.9, 142.5, 141.3, 138.1, 136.3, 133.9, 129.3, 128.7, 128.4, 128.1, 127.9, 127.8, 127.5, 126.6, 126.4, 126.2, 125.8, 125.4, 81.6, 72.8, 58.8, 52.5, 48.7, 35.6, 34.8 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₁H₃₀N₃O₂: 476.2333; found: 476.2324.



(S)-(3-benzyl-4-phenyl-1-(p-tolyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2yl)methanone: (3bb) Prepared from (1-methyl-1H-imidazol-2-yl)(3-(p-tolyl)bicyclo[1.1.0]butan-1-yl)methanone (1b, 50.5 mg, 0.20 mmol) and (Z)-N-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3bb as colorless oil (83.4 mg, 90% yield).

3bb: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 10.34 min, tr (major) = 21.60 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +90.2 (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.36 (d, *J* = 7.6 Hz, 2H), 7.28-7.23 (m, 2H), 7.21-7.18 (m, 4H), 7.13-7.08 (m, 7H), 6.86 (s, 1H), 4.83 (s, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.84 (AB, *J* = 14.8 Hz, 1H), 3.63 (t, *J* = 9.4 Hz, 1H), 3.40 (s, 3H), 2.90 (d, *J* = 9.6 Hz, 1H), 2.79 (t, *J* = 9.0 Hz, 1H), 2.39 (d, *J* = 10.0 Hz, 1H), 2.29 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.7, 142.6, 138.5, 138.2, 137.2, 129.1, 128.8, 128.6, 128.1, 128.0, 127.9, 127.8, 126.6, 125.8, 125.3, 81.6, 74.3, 58.5, 54.1, 49.8, 35.1, 34.9, 21.1 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2323.



(*S*)-(3-benzyl-1-(4-bromophenyl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3cb) Prepared from (3-(4-bromophenyl)bicyclo[1.1.0]butan-1yl)(1-methyl-1H-imidazol-2-yl)methanone (1c, 63.4 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3cb as colorless oil (100.4 mg, 95% yield).

3cb: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 11.66 min, tr (major) = 28.74 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_D^{20} = +82.1$ (*c* = 1.25, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.40 (d, *J* = 8.2 Hz, 2H), 7.35 (d, *J* = 7.6 Hz, 2H), 7.30-7.25 (m, 3H), 7.23-7.20 (m, 2H), 7.16-7.14 (m, 7H), 6.89 (s, 1H), 4.83 (s, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.83 (AB, *J* = 14.8 Hz, 1H), 3.62 (t, *J* = 9.2 Hz, 1H), 3.43 (s, 3H), 2.88 (d, *J* = 9.6 Hz, 1H), 2.78 (t, *J* = 9.2 Hz, 1H), 2.38 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.4, 142.6, 140.4, 138.1, 137.9, 131.3, 129.2, 128.6, 128.2, 127.89, 127.86, 127.2, 126.7, 126.0, 121.6, 81.2, 74.4, 58.6, 54.0, 49.8, 35.2, 35.1 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇BrN₃O₂: 528.1281; found: 528.1271.



(*S*)-(3-benzyl-1-(4-fluorophenyl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3db) Prepared from (3-(4-fluorophenyl)bicyclo[1.1.0]butan-1yl)(1-methyl-1H-imidazol-2-yl)methanone (1d, 51.2 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3db as colorless oil (87.6 mg, 94% yield).

3db: $\mathbf{R}_{\rm f}$ = 0.4 (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 10.27 min, tr (major) = 17.57 min) gave the isomeric composition of the product: 98% ee. [α]_D²⁰ = +89.7 (*c* = 1.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.35 (d, *J* = 8.0 Hz, 2H), 7.30-7.20 (m, 6H), 7.14 (s, 5H), 6.96 (d, *J* = 9.0 Hz, 2H), 6.88 (s, 1H), 4.83 (s, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.83 (d, *J* = 14.8 Hz, 1H), 3.63 (t, *J* = 9.4 Hz, 1H), 3.42 (s, 3H), 2.89 (d, *J* = 9.6 Hz, 1H), 2.79 (t, *J* = 9.2 Hz, 1H), 2.38 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.5, 162.2 (d, *J* = 245 Hz), 142.6, 138.1 (d, *J* = 11 Hz), 137.3 (d, *J* = 3 Hz), 129.2, 128.6, 128.2, 128.1, 127.9, 127.23, 127.15, 126.7, 125.9, 115.0 (d, *J* = 22 Hz), 81.3, 74.4, 58.6, 54.0, 49.8, 35.12, 35.06 ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -114.912 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇FN₃O₂: 468.2082; found: 468.2073.



(S)-(3-benzyl-4-phenyl-1-(4-(trifluoromethyl)phenyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1methyl-1H-imidazol-2-yl)methanone: (3eb) Prepared from (1-methyl-1H-imidazol-2-yl)(3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.0]butan-1-yl)methanone (1e, 61.2 mg, 0.20 mmol) and (Z)-N-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3eb** as colorless oil (86.6 mg, 84% yield).

3eb: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 9.51 min, tr (major) = 23.71 min) gave the isomeric composition of the product: 98% ee. $[\alpha]_{D}^{20} = +93.9$ (c = 1.00, CHCl₃). ¹H NMR (600 MHz, CDCl₃): δ 7.54 (d, J = 7.8 Hz, 2H), 7.39-7.35 (m, 4H), 7.30 (t, J = 7.2 Hz, 2H), 7.25-7.21 (m, 2H), 7.18-7.14 (m, 5H), 6.91 (s, 1H), 4.86 (s, 1H), 4.00 (AB, J = 14.8 Hz, 1H), 3.84 (AB, J = 14.8 Hz, 1H), 3.65 (t, J = 9.6 Hz, 1H), 3.45 (s, 3H), 2.93 (d, J = 9.6 Hz, 1H), 2.82 (t, J = 9.2 Hz, 1H), 2.43 (d, J = 10.0 Hz, 1H) ppm. ¹³C NMR (150 MHz, CDCl₃): δ 191.3, 145.1, 142.5, 138.0, 137.8, 129.7 (q, J = 32 Hz), 129.2, 128.6, 128.23, 128.21, 127.9, 127.8, 126.8, 126.0, 125.7, 125.2 (q, J = 4 Hz), 124.1 (q, J = 270 Hz), 81.2, 74.5, 58.7, 54.1, 49.9, 35.2 ppm. ¹⁹F NMR (565 MHz, CDCl₃) δ -62.520 ppm. HRMS (ESI) *m/z*: [M+K]⁺ calcd. for C₃₀H₂₆F₃N₃O₂K: 556.1609; found: 556.1603.



(S)-(3-benzyl-4-phenyl-1-(*m*-tolyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2yl)methanone: (3fb) Prepared from (1-methyl-1H-imidazol-2-yl)(3-(*m*tolyl)bicyclo[1.1.0]butan-1-yl)methanone (1f, 50.5 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3fb** as a white solid (79.7 mg, 86% yield).

3fb: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 121-123 °C. HPLC analysis (Chiralpak AD-H, 'PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (minor) = 5.06 min, tr (major) = 6.24 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +84.9 (*c* = 2.00, CHCl₃). ¹H **NMR** (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.6 Hz, 2H), 7.27 (t, *J* = 7.6 Hz, 2H), 7.23-7.17 (m, 3H), 7.16-7.08 (m, 7H), 7.04 (d, *J* = 7.6 Hz, 1H), 6.87 (s, 1H), 4.83 (s, 1H), 3.99 (AB, *J* = 14.8 Hz, 1H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.64 (t, *J* = 9.4 Hz, 1H), 3.41 (s, 3H), 2.92 (d, *J* = 9.6 Hz, 1H), 2.79 (t, *J* = 9.2 Hz, 1H), 2.40 (d, *J* = 10.0 Hz, 1H), 2.28 (s, 3H) ppm. ¹³C **NMR** (100 MHz, CDCl₃): δ 191.7, 142.6, 141.3, 138.2, 138.1, 137.7, 129.1, 128.7, 128.3, 128.10, 128.06, 127.9, 127.8, 126.6, 126.2, 125.9, 122.4, 81.7, 74.4, 58.5, 54.1, 49.7, 35.1, 35.1, 21.4 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2326.



(S)-(3-benzyl-1-(3-chlorophenyl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-

imidazol-2-yl)methanone: **(3gb)** Prepared from (3-(3-chlorophenyl)bicyclo[1.1.0]butan-1yl)(1-methyl-1H-imidazol-2-yl)methanone (**1g**, 54.5 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (**2b**, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3gb** as a white solid (90.0 mg, 93% yield).

3gb: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 137-139 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 8.06 min, tr (major) = 11.52 min) gave the isomeric composition of the product: 98% ee. $[\alpha]_{D}^{20}$ = +84.3 (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.36 (d, *J* = 7.2 Hz, 2H), 7.31-7.27 (m, 3H), 7.24-7.19 (m, 4H), 7.14 (s, 6H), 6.88 (s, 1H), 4.84 (s, 1H), 3.99 (AB, *J* = 14.8 Hz, 1H), 3.84 (AB, *J* = 14.8 Hz, 1H), 3.62 (t, *J* = 9.4 Hz, 1H), 3.42 (s, 3H), 2.89 (d, *J* = 10.0 Hz, 1H), 2.79 (t, *J* = 9.2 Hz, 1H), 2.39 (d, *J* = 10.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.3, 143.3, 142.5, 138.0, 137.9, 134.1, 129.5, 129.2, 128.7, 128.2, 127.9, 127.8, 127.6, 126.8, 126.0, 125.9, 123.5, 81.2, 74.4, 58.6, 54.0, 49.9, 35.1 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₉H₂₇ClN₃O₂: 484.1786; found: 484.1778.



(*S*)-(3-benzyl-4-phenyl-1-(o-tolyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2yl)methanone: (3hb) Prepared from (1-methyl-1H-imidazol-2-yl)(3-(otolyl)bicyclo[1.1.0]butan-1-yl)methanone (1h, 50.5 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3hb as colorless oil (83.4 mg, 90% yield). **3hb**: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 10.12 min, tr (major) = 15.60 min) gave the isomeric composition of the product: 94% ee. $[\alpha]_{D}^{20} = +111.5$ (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.29 (d, *J* = 7.2 Hz, 2H), 7.24-7.22 (m, 3H), 7.19-7.09 (m, 9H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.87 (s, 1H), 4.82 (s, 1H), 3.93 (AB, *J* = 14.4 Hz, 1H), 3.88 (t, *J* = 9.0 Hz, 1H), 3.74 (AB, *J* = 14.4 Hz, 1H), 3.39 (s, 3H), 2.98-2.91 (m, 2H), 2.36 (d, *J* = 10.0 Hz, 1H), 2.19 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.6, 142.7, 138.5, 138.3, 138.2, 130.9, 129.1, 129.0, 128.2, 128.12, 128.06, 127.9, 127.7, 126.66, 126.65, 125.8, 125.2, 82.9, 74.3, 58.7, 54.0, 49.2, 35.1, 33.4, 19.6 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2325.



(*S*)-(3-benzyl-1-(naphthalen-2-yl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1Himidazol-2-yl)methanone: (3ib) Prepared from (1-methyl-1H-imidazol-2-yl)(3-(naphthalen-2-yl)bicyclo[1.1.0]butan-1-yl)methanone (1i, 57.7 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3ib as a white solid (83.9 mg, 84% yield).

3ib: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 123-125 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 9.25 min, tr (major) = 28.45 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +115.5 (*c* = 2.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.78-7.71 (m, 4H), 7.45-7.39 (m, 5H), 7.30 (t, *J* = 7.6 Hz, 2H), 7.25-7.23 (m, 2H), 7.16 (s, 5H), 6.88 (s, 1H), 4.89 (s, 1H), 4.02 (AB, *J* = 14.6 Hz, 1H), 3.88 (AB, *J* = 14.8 Hz, 1H), 3.72 (t, *J* = 9.4 Hz, 1H), 3.42 (s, 3H), 3.05

(d, J = 8.4 Hz, 1H), 2.90 (t, J = 9.1 Hz, 1H), 2.49 (d, J = 10.0 Hz, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 191.6, 142.6, 138.7, 138.2, 138.1, 133.0, 132.8, 129.2, 128.8, 128.2, 128.1, 127.92, 127.90, 127.86, 127.5, 126.7, 125.94, 125.92, 125.88, 124.4, 123.6, 81.8, 74.5, 58.7, 54.2, 49.8, 35.1, 35.1 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₃H₃₀N₃O₂: 500.2333; found: 500.2322.



(S)-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-ethyl-1H-imidazol-2yl)methanone: (3jb) Prepared from ((1-ethyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1j, 50.4 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3jb as a white solid (74.1 mg, 80% yield).

3jb: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 107-109 °C. HPLC analysis (Chiralpak AD-H, 'PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 8.56 min, tr (major) = 16.27 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +78.1 (*c* = 1.75, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.6 Hz, 2H), 7.30-7.21 (m, 9H), 7.16-7.13 (m, 5H), 6.95 (s, 1H), 4.90 (s, 1H), 4.16-4.08 (m, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.86 (AB, *J* = 15.2 Hz, 1H), 3.80-3.73 (m, 1H), 3.67 (t, *J* = 9.4 Hz, 1H), 2.94 (d, *J* = 9.6 Hz, 1H), 2.82 (t, *J* = 9.0 Hz, 1H), 2.42 (d, *J* = 10.4 Hz, 1H), 0.87 (t, *J* = 7.0 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.4, 141.7, 141.4, 138.3, 138.2, 129.3, 128.6, 128.20, 128.15, 128.0, 127.8, 127.5, 126.6, 125.4, 124.5, 81.7, 74.5, 58.5, 54.2, 50.0, 43.2, 35.1, 15.9 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2331.



(S)-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-propyl-1H-imidazol-2-

yl)methanone: (**3kb**) Prepared from ((1-propyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone (**1k**, 53.2 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (**2b**, 50.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3x** as a white solid (77.4 mg, 81% yield).

3kb: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 115-117 °C. HPLC analysis (Chiralpak AD-H, *i*PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 8.04 min, tr (major) = 15.44 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{26}$ = +61.4 (*c* = 1.88, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.6 Hz, 2H), 7.30-7.26 (m, 6H), 7.25-7.21 (m, 3H), 7.19-7.17 (m, 2H), 7.13-7.12 (m, 3H), 6.93 (s, 1H), 4.92 (s, 1H), 4.19-4.12 (m, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.86 (AB, *J* = 14.8 Hz, 1H), 3.70-3.60 (m, 2H), 2.93 (d, *J* = 9.6 Hz, 1H), 2.81 (t, *J* = 9.0 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H), 1.26-1.12 (m, 2H), 0.64 (t, *J* = 7.4 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.3, 141.7, 141.4, 138.3, 138.2, 129.1, 128.6, 128.22, 128.15, 128.1, 128.0, 127.8, 127.5, 126.6, 125.42, 125.40, 81.7, 74.5, 58.5, 54.2, 50.0, 49.8, 35.2, 23.7, 10.9 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₁H₃₂N₃O₂: 478.2489; found: 478.2484.



(S)-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-isopropyl-1H-imidazol-2yl)methanone: (3lb) Prepared from ((1-isopropyl-1H-imidazol-2-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (**1I**, 53.2 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (**2b**, 50.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3lb** as a white solid (69.7 mg, 73% yield).

3Ib: $\mathbf{R}_{f} = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 101-103 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 6.65 min, tr (major) = 21.65 min) gave the isomeric composition of the product: 98% ee. [α]_D²⁰ = +37.3 (*c* = 1.75, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.6 Hz, 2H), 7.32-7.28 (m, 9H), 7.19-7.11 (m, 6H), 4.91-4.85 (m, 2H), 3.97 (AB, *J* = 14.8 Hz, 1H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.66 (t, *J* = 9.2 Hz, 1H), 2.95 (d, *J* = 9.6 Hz, 1H), 2.83 (t, *J* = 9.2 Hz, 1H), 2.43 (d, *J* = 10.0 Hz, 1H), 1.30 (d, *J* = 6.8 Hz, 3H), 0.81 (d, *J* = 5.6 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.6, 141.7, 141.4, 138.3, 129.6, 128.6, 128.2, 128.13, 128.06, 127.9, 127.8, 127.5, 126.6, 125.4, 120.3, 81.7, 74.6, 58.4, 54.5, 50.2, 48.6, 35.1, 23.2, 23.0 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₁H₃₂N₃O₂: 478.2489; found: 478.2487.



(S)-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-cyclohexyl-1H-imidazol-2-yl)(3-yl)methanone: (3mb) Prepared from ((1-cyclohexyl-1H-imidazol-2-yl)(3-phenylbicyclo[1.1.0]butan-1-yl)methanone (1m, 58.8 mg, 0.20 mmol) and (Z)-N-benzyl-1-phenylmethanimine oxide (2b, 50.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded 3mb as a white solid (72.0 mg, 71% yield).

3mb: $\mathbf{R}_f = 0.4$ (petroleum ether/EtOAc = 3/1). Mp: 125-127 °C. HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 15/85, 1.0 mL/min, 254 nm; tr (minor) = 6.51 min, tr (major) = 25.27 min) gave the isomeric composition of the product: 98% ee. $[\alpha]_D^{20}$ =

+27.5 (*c* = 1.75, CHCl₃). ¹**H NMR** (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.6 Hz, 2H), 7.30-7.21 (m, 9H), 7.16-7.11 (m, 6H), 4.90 (s, 1H), 4.43-4.35 (m, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.66 (t, *J* = 9.6 Hz, 1H), 2.95 (d, *J* = 9.6 Hz, 1H), 2.83 (t, *J* = 9.2 Hz, 1H), 2.43 (d, *J* = 10.0 Hz, 1H), 1.98 (d, *J* = 10.4 Hz, 1H), 1.77 (d, *J* = 12.0 Hz, 1H), 1.62 (d, *J* = 11.6 Hz, 2H), 1.40-1.26 (m, 2H), 1.17-1.06 (m, 4H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 191.7, 141.8, 141.4, 138.2, 129.4, 128.6, 128.2, 128.1, 128.0, 127.84, 127.81, 127.5, 126.6, 125.4, 120.8, 81.7, 74.6, 58.4, 56.2, 54.5, 50.2, 35.1, 34.0, 33.8, 25.40, 25.36, 25.2 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₄H₃₆N₃O₂: 518.2802; found: 518.2796.



(*S*)-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(3,5-dimethyl-1H-pyrazol-1yl)methanone: (3nb) Prepared from (3,5-dimethyl-1H-pyrazol-1-yl)(3phenylbicyclo[1.1.0]butan-1-yl)methanone (1n, 50.5 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (20/1) afforded **3nb** as a white solid (91.9 mg, 99% yield).

3nb: $\mathbf{R}_{f} = 0.6$ (petroleum ether/EtOAc = 10/1). Mp: 103-105 °C. HPLC analysis (Chiralpak AD-H, *i*PrOH/hexane = 2/98, 1.0 mL/min, 254 nm; tr (major) = 9.53 min, tr (minor) = 13.49 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{20} = +62.8$ (c = 0.50, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.38 (d, J = 8.0 Hz, 2H), 7.31-7.27 (m, 6H), 7.24-7.20 (m, 2H), 7.17 (s, 5H), 5.84 (s, 1H), 4.81 (s, 1H), 4.02 (AB, J = 14.8 Hz, 1H), 3.84 (AB, J = 14.8 Hz, 1H), 3.72 (t, J = 9.6 Hz, 1H), 2.96 (d, J = 9.6 Hz, 1H), 2.74 (t, J = 9.4 Hz, 1H), 2.41 (d, J = 10.0 Hz, 1H), 2.30 (s, 3H), 2.05 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 172.6, 151.9, 144.0, 141.2, 138.1, 137.7, 128.7, 128.3, 128.2, 128.1, 127.8, 127.53, 127.47, 126.7, 125.3, 110.2, 81.5, 73.6, 58.7, 51.7, 50.0,

35.9, 13.9, 13.5 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₃₀N₃O₂: 464.2333; found: 464.2319.



(S)-(3-benzyl-4-phenyl-1-(4-(trifluoromethyl)phenyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(3,5dimethyl-1H-pyrazol-1-yl)methanone: (3ob) Prepared from (3,5-dimethyl-1H-pyrazol-1yl)(3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.0]butan-1-yl)methanone (1o, 64.0 mg, 0.20 mmol) and (Z)-*N*-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (20/1) afforded **3ob** as a colorless oil (89.0 mg, 84% yield).

3ob: $\mathbf{R}_r = 0.6$ (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak OD-H, /PrOH/hexane = 2/98, 0.8 mL/min, 254 nm; tr (major) = 5.83 min, tr (minor) = 6.52 min) gave the isomeric composition of the product: 92% ee. [α]_D²⁰ = +49.0 (*c* = 1.00, CHCl₃). ¹**H NMR** (400 MHz, CDCl₃): δ 7.54 (d, *J* = 8.0 Hz, 2H), 7.38 (d, *J* = 8.0 Hz, 4H), 7.31 (d, *J* = 7.2 Hz, 2H), 7.26-7.23 (m, 1H), 7.20-7.16 (m, 5H), 5.86 (s, 1H), 4.82 (s, 1H), 4.02 (AB, *J* = 14.4 Hz, 1H), 3.84 (AB, *J* = 14.4 Hz, 1H), 3.72 (t, *J* = 9.6 Hz, 1H), 2.97 (d, *J* = 10.0 Hz, 1H), 2.76 (t, *J* = 9.2 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H), 2.31 (s, 3H), 2.06 (s, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 172.3, 152.2, 144.9, 144.1, 137.9, 137.4, 129.7 (q, *J* = 32 Hz), 128.7, 128.41, 128.38, 127.9, 127.4, 126.8, 125.7, 125.2 (q, *J* = 4 Hz), 124.1 (q, *J* = 270 Hz), 110.4, 81.1, 73.7, 58.8, 51.8, 50.2, 36.1, 13.9, 13.5 ppm. ¹⁹**F NMR** (376 MHz, CDCl₃) δ -62.528 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₃₁H₂₈F₃N₃O₂: 532.2206; found: 532.2213.



(S)-(3-benzyl-4-phenyl-1-(m-tolyl)-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(3,5-dimethyl-1H-pyrazol-1-yl)methanone: (**3pb**) Prepared from (3,5-dimethyl-1H-pyrazol-1-yl)(3-(mtolyl)bicyclo[1.1.0]butan-1-yl)methanone (1p, 53.2 mg, 0.20 mmol) and (Z)-N-benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the GP1 at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (20/1) afforded **3pb** as a colorless oil (95.4 mg, 99% yield).

3pb: $\mathbf{R}_f = 0.6$ (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak AD-H, PrOH/hexane = 2/98, 1.0 mL/min, 254 nm; tr (major) = 6.69 min, tr (minor) = 9.00 min) gave the isomeric composition of the product: 99.5% ee. $[\alpha]_D^{20} = +58.0$ (*c* = 1.25, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.31 (d, *J* = 7.6 Hz, 2H), 7.22 (t, *J* = 7.6 Hz, 2H), 7.16-7.11 (m, 2H), 7.08 (s, 5H), 7.02-6.95 (m, 3H), 5.75 (s, 1H), 4.72 (s, 1H), 3.94 (AB, J = 14.8 Hz, 1H), 3.76 (AB, J = 14.8 Hz, 1H), 3.62 (t, J = 9.6 Hz, 1H), 2.88 (d, J = 10.0 Hz, 1H), 2.65 (t, J = 9.2 Hz, 1H), 2.31 (d, J = 10.0 Hz, 1H), 2.22 (s, 3H), 2.20 (s, 3H), 1.97 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 172.6, 151.9, 144.0, 141.1, 138.1, 137.74, 137.69, 128.8, 128.3, 128.2, 128.1, 127.8, 127.5, 126.7, 126.2, 122.4, 110.2, 81.5, 73.5, 58.7, 51.8, 49.9, 36.0, 21.4, 13.9, 13.5 ppm. HRMS (ESI) m/z: [M+H]⁺ calcd. for C₃₁H₃₂N₃O₂: 478.2489; found: 478.2501.



M = 481.57 g/mol

(S)-(3-benzyl-1-(4-fluorophenyl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(3,5-dimethyl-1Hpyrazol-1-yl)methanone: (3qb) Prepared from (3,5-dimethyl-1H-pyrazol-1-yl)(3-(4fluorophenyl)bicyclo[1.1.0]butan-1-yl)methanone (1q, 54.0 mg, 0.20 mmol) and (*Z*)-*N*benzyl-1-phenylmethanimine oxide (2b, 50.7 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (20/1) afforded 3qb as a colorless oil (93.4 mg, 97% yield).

3qb: $\mathbf{R}_{f} = 0.6$ (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 1/99, 1.0 mL/min, 254 nm; tr (major) = 12.55 min, tr (minor) = 16.69 min) gave the isomeric composition of the product: 99% ee. $[\alpha]_{D}^{20} = +56.7$ (*c* = 1.50, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 6.8 Hz, 2H), 7.30 (t, *J* = 7.4 Hz, 2H), 7.26-7.22 (m, 3H), 7.16 (s, 5H), 6.96 (t, *J* = 8.8 Hz, 2H), 5.85 (s, 1H), 4.80 (s, 1H), 4.01 (AB, *J* = 14.8 Hz, 1H), 3.83 (AB, *J* = 14.8 Hz, 1H), 3.70 (t, *J* = 9.6 Hz, 1H), 2.93 (d, *J* = 10.0 Hz, 1H), 2.73 (t, *J* = 9.4 Hz, 1H), 2.37 (d, *J* = 10.4 Hz, 1H), 2.31 (s, 3H), 2.05 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 172.4, 162.2 (d, *J* = 244 Hz), 152.0, 144.1, 138.0, 137.6, 137.1 (d, *J* = 3 Hz), 128.7, 128.3, 127.9, 127.5, 127.1 (d, *J* = 8 Hz), 126.7, 115.0 (d, *J* = 22 Hz), 110.3, 81.1, 73.6, 58.7, 51.7, 50.0, 36.0, 13.9, 13.5 ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -114.853 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₃₀H₂₉FN₃O₂: 482.2238; found: 482.2227.



(S)-(3,5-dimethyl-1H-pyrazol-1-yl)(1,3,4-triphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)methanone: (3nd)^[3a] Prepared from (3,5-dimethyl-1H-pyrazol-1-yl)(3-phenylbicyclo[1.1.0]butan-1yl)methanone (1n, 50.5 mg, 0.20 mmol) and (*Z*)-N,1-diphenylmethanimine oxide (2d, 47.3 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (20/1) afforded **3nd** as a white solid (48.0 mg, 53% yield). **3nd**: $\mathbf{R}_f = 0.6$ (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 2/98, 1.0 mL/min, 254 nm; tr (major) = 9.29 min, tr (minor) = 10.91 min) gave the isomeric composition of the product: 28% ee. $[\alpha]_D^{20} = +14.9$ (*c* = 1.20, CHCl₃).¹**H NMR** (400 MHz, CDCl₃): δ 7.50-7.48 (m,2H), 7.43-7.40 (m, 2H), 7.36-7.35 (m, 1H), 7.21-7.16 (m, 7H), 7.07-7.05 (m, 2H), 6.89-6.86 (m, 1H), 5.94 (s, 2H), 3.25 (t, *J* = 9.4 Hz, 1H), 3.18 (t, *J* = 9.4 Hz, 1H), 2.77 (d, *J* = 10.0 Hz, 1H), 2.58 (d, *J* = 10.4 Hz, 1H), 2.31 (s, 3H), 2.25 (s, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 172.0, 152.4, 150.0, 144.30, 140.29, 138.3, 128.9, 128.5, 128.4, 128.3, 128.2, 127.1, 125.9, 121.5, 116.7, 110.7, 83.5, 70.2, 51.8, 45.3, 36.6, 13.97, 13.91 ppm.



(S)-(3-benzyl-1-methyl-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-propyl-1H-imidazol-2yl)methanone: (3rb) Prepared from (3-methylbicyclo[1.1.0]butan-1-yl)(1-propyl-1Himidazol-2-yl)methanone (1r, 40.8 mg, 0.20 mmol) and (*Z*)-*N*-benzyl-1phenylmethanimine oxide (2b, 50.6 mg, 0.24 mmol) according to the **GP1** at rt for 16 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (5/1) afforded **3rb** as a colorless oil (25.0 mg, 30% yield).

3rb: $\mathbf{R}_{f} = 0.6$ (petroleum ether/EtOAc = 3/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (minor) = 5.67 min, tr (major) = 14.57 min) gave the isomeric composition of the product: 24% ee. $[\alpha]_{D}^{20} = +5.1$ (c = 0.51, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.37-7.31 (m, 2H), 7.26 (t, J = 7.6 Hz, 2H), 7.21-7.18 (m, 2H), 7.12-7.09 (m, 5H), 6.90 (s, 1H), 4.77 (s, 1H), 4.14-4.07 (m, 1H), 3.89 (AB, J = 14.8 Hz, 1H), 3.75 (AB, J = 14.8 Hz, 1H), 3.64-3.57 (m, 1H), 3.30 (t, J = 9.4 Hz, 1H), 2.51 (t, J = 9.2 Hz, 1H), 2.32 (d, J = 9.6 Hz, 1H), 2.10 (d, J = 10.0 Hz, 1H), 1.27 (s, 3H), 1.21-1.11 (m, 2H), 0.63 (t, J = 7.4 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.6, 141.7, 138.4, 138.4, 129.0, 128.6, 128.1, 128.0, 127.82, 127.80, 126.5, 125.2, 79.1, 74.3, 58.5, 54.6, 51.3, 49.8, 33.6, 23.7, 23.4, 10.9 ppm. **HRMS** (ESI) m/z: [M+Na]⁺ calcd. for C₂₆H₂₉N₃O₂Na: 438.2152; found: 438.2158.



(S)-3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptane-5-carbaldehyde (4nb): Prepared from (S)-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(3,5dimethyl-1H-pyrazol-1-yl)methanone (**3nb**, 46.3 mg, 0.1 mmol) according to the **GP3** at -40 °C for 30 min. Purification by flash chromatography on silica gel using petroleum ether/ethyl acetate (10/1) afforded **4nb** as a colorless oil (20.0 mg, 54% yield).

4nb: **R**_{*f*} = 0.4 (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak AD-H, ^{*i*}PrOH/hexane = 2/98, 1.0 mL/min, 254 nm; tr (minor) = 7.54 min, tr (major) = 8.66 min) gave the isomeric composition of the product: 99% ee. $[α]_D^{20}$ = +99.0 (*c* = 0.50, CHCl₃). ¹**H NMR** (600 MHz, CDCl₃): δ 9.23 (s, 1H), 7.53-7.52 (m, 2H), 7.40-7.38 (m, 2H), 7.36-7.33 (m, 3H), 7.32-7.28 (m, 6H), 7.27-7.23 (m, 2H), 4.29 (s, 1H), 4.13 (AB, *J* = 14.8 Hz, 1H), 3.81 (AB, *J* = 14.8 Hz, 1H), 3.53 (t, *J* = 9.6 Hz, 1H), 2.69 (d, *J* = 9.6 Hz, 1H), 2.30 (d, *J* = 9.6 Hz, 1H), 2.06 (t, *J* = 9.0 Hz, 1H) ppm. ¹³**C NMR** (150 MHz, CDCl₃): δ 200.5, 140.7, 137.28, 137.25, 129.2, 129.1, 128.9, 128.3, 128.0, 127.94, 127.89, 127.0, 125.3, 81.7, 72.0, 58.1, 52.2, 45.8, 35.1 ppm. **HRMS** (ESI) *m/z*: [M+Na]⁺ calcd. for C₂₅H₂₃NO₂Na: 392.1621; found: 392.1624.



(*S*)-3-benzyl-1-(4-fluorophenyl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptane-5-carbaldehyde (4qb): Prepared from (*S*)-(3-benzyl-1-(4-fluorophenyl)-4-phenyl-2-oxa-3azabicyclo[3.1.1]heptan-5-yl)(3,5-dimethyl-1H-pyrazol-1-yl)methanone (**3qb**, 48.1 mg, 0.1 mmol) according to the **GP3** at -40 °C for 30 min. Purification by flash chromatography on silica gel using petroleum ether/ethyl acetate (10/1) afforded **4qb** as a colorless oil (23.3 mg, 60% yield).

(4qb): **R**_f = 0.4 (petroleum ether/EtOAc = 10/1). [α]_D²⁰ = +133.6 (*c* = 0.70, CHCl₃). ¹H **NMR** (400 MHz, CDCl₃): δ 9.22 (s, 1H), 7.52 (d, *J* = 7.2 Hz, 2H), 7.41-7.28 (m, 7H), 7.26-7.22 (m, 3H), 6.98 (t, *J* = 8.6 Hz, 2H), 4.28 (s, 1H), 4.11 (AB, *J* = 14.8 Hz, 1H), 3.79 (AB, *J* = 14.8 Hz, 1H), 3.51 (t, *J* = 9.2 Hz, 1H), 2.66 (d, *J* = 9.2 Hz, 1H), 2.26 (d, *J* = 9.6 Hz, 1H), 2.05 (t, *J* = 9.2 Hz, 1H) ppm. ¹³C **NMR** (100 MHz, CDCl₃): δ 200.4, 162.4 (d, *J* = 146 Hz), 137.2 (d, *J* = 7 Hz), 136.6 (d, *J* = 3 Hz), 129.2, 129.0, 128.0, 127.2, 127.1, 127.0, 115.1 (d, *J* = 21 Hz), 81.2, 72.0, 58.1, 52.1, 45.8, 35.3 ppm. ¹⁹F **NMR** (376 MHz, CDCl₃) δ -114.222 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₂₅H₂₃FNO₂: 388.1707; found: 388.1702.



(*S*)-1-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)ethan-1-one (5): $\mathbf{R}_{f} = 0.3$ (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 10/90, 1.0 mL/min, 254 nm; tr (minor) = 5.06 min, tr (major) = 6.24 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +53.2 (*c* = 0.58, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.50-7.47 (m, 2H), 7.37-7.23 (m, 13H), 4.25 (s, 1H), 4.09 (AB, *J* = 14.8 Hz, 1H), 3.79 (d, *J* = 14.8 Hz, 1H), 3.60 (t, *J* = 9.4 Hz, 1H), 2.59 (d, *J* = 9.6 Hz, 1H), 2.29 (d, *J* = 10.0 Hz, 1H), 2.21 (t, *J* = 9.2 Hz, 1H), 1.68 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 208.8, 140.8, 137.5, 137.4, 129.0, 128.9, 128.8, 128.3, 128.2, 127.9, 127.8, 126.9, 125.3, 80.6, 73.2, 58.3, 54.4, 47.4, 35.3, 26.6 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₂₆H₂₆NO₂: 384.1958; found: 384.1950.



Methyl (*S*)-3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptane-5-carboxylate (**6**): $\mathbf{R}_f = 0.6$ (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak AD-H, [/]PrOH/hexane = 2/98, 1.0 mL/min, 254 nm; tr (minor) = 9.25 min, tr (major) = 10.40 min) gave the isomeric composition of the product: 98% ee. [α]_D²⁰ = +65.4 (*c* = 1.00, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (d, *J* = 6.4 Hz, 2H), 7.36-7.22 (m, 13H), 4.24 (s, 1H), 4.09 (AB, *J* = 14.8 Hz, 1H), 3.80 (AB, *J* = 14.8 Hz, 1H), 3.58 (t, *J* = 9.6 Hz, 1H), 3.31 (s, 3H), 2.72 (d, *J* = 9.4 Hz, 1H), 2.37 (d, *J* = 10.0 Hz, 1H), 2.22 (t, *J* = 9.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 172.7, 140.8, 137.9, 137.4, 129.0, 128.5, 128.4, 128.2, 128.1, 127.9, 127.7, 126.9, 125.3, 81.3, 73.1, 58.6, 51.3, 48.6, 47.7, 35.7 ppm. HRMS (ESI) *m/z*: [M+H]⁺ calcd. for C₂₆H₂₆NO₃: 400.1907; found: 400.1901.



(S)-2-(3-benzyl-1,4-diphenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)propan-2-ol (7): $\mathbf{R}_{f} = 0.3$ (petroleum ether/EtOAc = 10/1). HPLC analysis (Chiralpak AD-H, /PrOH/hexane = 5/95, 0.8 mL/min, 254 nm; tr (minor) = 12.11 min, tr (major) = 12.63 min) gave the isomeric composition of the product: 99% ee. [α]_D²⁰ = +22.0 (*c* = 0.75, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.60 (s, 1H), 7.38-7.21 (m, 14H), 4.09 (s, 1H), 3.98 (AB, *J* = 14.6 Hz, 1H), 3.66 (d, *J* = 14.8 Hz, 1H), 3.32 (t, *J* = 9.2 Hz, 1H), 2.82 (d, *J* = 9.6 Hz, 1H), 2.22 (d, *J* = 10.0 Hz, 1H), 1.79 (t, *J* = 9.0 Hz, 1H), 1.12 (s, 3H), 0.65 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 142.1, 140.0, 138.0, 130.0, 129.1, 128.6, 128.1, 127.8, 127.4, 126.7, 125.4, 80.0, 74.9, 72.0, 58.4, 50.7, 43.8, 33.2, 26.4, 25.4 ppm. **HRMS** (ESI) *m/z*: [M+H]⁺ calcd. for C₂₇H₃₀NO₂: 400.2271; found: 400.2263.



(S)-(1-(amino(phenyl)methyl)-3-hydroxy-3-phenylcyclobutyl)(3,5-dimethyl-1H-pyrazol-1-

yl)methanone (8): \mathbf{R}_f = 0.5 (petroleum ether/EtOAc = 1/1). [α]_D²⁰ = +32.7 (*c* = 0.30, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (d, *J* = 8.4, 2H), 7.32 (t, *J* = 7.4 Hz, 2H), 7.22-7.20 (m, 4H), 6.93-6.91 (m, 2H), 5.87 (s, 1H), 5.06 (s, 1H), 3.48 (d, *J* = 14.0 Hz, 1H), 3.26 (d, *J* = 14.4 Hz, 1H), 3.04 (dd, *J* = 14.4, 4.4 Hz, 1H), 2.85 (dd, *J* = 14.4, 4.0 Hz, 1H), 2.26 (s, 3H), 2.17 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 174.5, 151.5, 146.1, 144.5, 143.1, 128.6, 128.1, 127.8, 126.6, 125.8, 125.0, 110.2, 71.2, 57.6, 50.4, 50.3, 40.3, 14.02, 13.95 ppm. HRMS (ESI) *m/z*: [M+K]⁺ calcd. for C₂₃H₂₅N₃O₂K: 414.1578; found: 414.1582.



N-(((*S*)-3-benzyl-1-(4-fluorophenyl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)methyl)-1-(chroman-2-yl)methanamine (9): $\mathbf{R}_f = 0.3$ (petroleum ether/EtOAc = 3/1). [α]_D²⁰ = +50.8 (*c* = 0.25, CHCl₃). ¹H NMR (600 MHz, CDCl₃): δ 7.55 (d, *J* = 7.2 Hz, 2H), 7.35-7.30 (m, 5H), 7.28-7.25 (m, 4H), 7.22 (t, *J* = 7.2 Hz, 1H), 7.10-7.07 (m, 1H), 7.03 (d, *J* = 7.8 Hz, 1H), 6.97 (t, *J* = 8.4 Hz, 2H), 6.83 (t, *J* = 7.8 Hz, 1H), 6.78 (t, *J* = 9.0 Hz, 1H), 4.08 (s, 1H), 4.04-3.92 (m, 2H), 3.76-3.73 (m, 1H), 3.35-3.31 (m, 1H), 2.84-2.78 (m, 1H), 2.722.69 (m, 1H), 2.60-2.53 (m, 1H), 2.50-2.46 (m, 1H), 2.30-2.22 (m, 2H), 1.98-1.94 (m, 1H), 1.89-1.83 (m, 2H), 1.74-1.65 (m, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 162.2 (d, *J* = 244 Hz) 154.6, 139.1, 139.0, 138.1, 137.9, 129.6, 129.5, 128.9, 128.50, 128.45, 128.12, 128.09, 127.8, 127.21, 127.18, 127.15, 127.13, 126.7, 122.0, 120.1, 116.7, 116.6, 115.0, 114.8, 81.9, 81.8, 75.3, 75.3, 75.1, 74.9, 59.1, 55.0, 54.73, 54.68, 54.6, 46.0, 45.9, 43.6, 43.5, 36.7, 36.5, 25.5, 25.4, 24.6 ppm. ¹⁹**F NMR** (565 MHz, CDCl₃) δ -115.186 ppm. **HRMS** (ESI) *m/z*: [M+Na]⁺ calcd. for C₃₅H₃₅FN₂O₂: 535.2755; found: 535.2744.



(**S**)-3-benzyl-5-((4-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperazin-1-yl)methyl)-1-(4-fluorophenyl)-4-phenyl-2-oxa-3-azabicyclo[3.1.1]heptane (10): **R**_f = 0.2 (petroleum ether/EtOAc = 10/1). [α]_D²⁰ = +24.5 (*c* = 0.20, CHCl₃). ¹H NMR (600 MHz, CDCl₃): δ 7.58 (d, *J* = 6.6 Hz, 2H), 7.35-7.31 (m, 4H), 7.29-7.20 (m, 6H), 6.96 (t, *J* = 9.0 Hz, 2H), 6.78 (t, *J* = 7.8 Hz, 1H), 6.59 (dd, *J* = 8.4, 1.2 Hz, 1H), 6.54 (dd, *J* = 7.8, 1.2 Hz, 1H), 4.29-4.28 (m, 2H), 4.23-4.22 (m, 2H), 4.16 (s, 1H), 4.03 (AB, *J* = 14.8 Hz, 1H), 3.75 (AB, *J* = 14.8 Hz, 1H), 3.32 (t, *J* = 9.0 Hz, 1H), 2.98 (s, 4H), 2.56 (s, 2H), 2.50 (d, *J* = 9.0 Hz, 1H), 2.14-2.06 (m, 4H), 1.98 (d, *J* = 13.2 Hz, 1H), 1.79 (d, *J* = 9.6 Hz, 1H) ppm. ¹³C NMR (150 MHz, CDCl₃): δ 162.1 (d, *J* = 243 Hz), 144.1, 141.9, 139.2, 138.3, 137.9 (d, *J* = 5 Hz), 136.4, 129.4, 128.8, 127.9, 127.8, 127.7, 127.1 (d, *J* = 9 Hz), 126.6, 120.6, 114.9 (d, *J* = 21 Hz), 111.8, 110.5, 82.5, 75.6, 64.3, 63.9, 63.6, 59.1, 54.1, 50.9, 48.5, 43.1, 37.3 ppm. ¹⁹F NMR (565 MHz, CDCl₃) δ -115.24 ppm. HRMS (ESI) *m/z*: [M+Na]⁺ calcd. for C₃₇H₃₈FN₃O₃Na: 614.2789; found: 614.2775.



((4*S*)-4-(4-(1-((6-(3-(adamantan-1-yl)-4-methoxyphenyl)naphthalen-2-yl)methyl)-1H-1,2,3-triazol-4-yl)phenyl)-3-benzyl-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1methyl-1H-imidazol-2-yl)methanone (11): Prepared from (*S*)-(3-benzyl-4-(4ethynylphenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)methanone (**3as**, 20.0 mg, 0.042 mmol) and 1-(5-(6-(azidomethyl)naphthalen-2yl)-2-methoxyphenyl)adamantane (26.7 mg, 0.063 mmol) according to the **GP4** at rt for 5 h. Purification by flash chromatography on silica gel using petroleum ether/EtOAc (4/1) afforded **11** as a white solid (37.7 mg, 99% yield).

11: $\mathbf{R}_{r} = 0.2$ (petroleum ether/EtOAc = 2/1). [α]_D²⁰ = +0.9 (*c* = 1.00, CHCl₃). Mp: 141-143 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.98 (s, 1H), 7.87 (t, *J* = 9.8 Hz, 2H), 7.78-7.76 (m, 2H), 7.62-7.57 (m, 4H), 7.52 (d, *J* = 8.4 Hz, 1H), 7.38-7.33 (m, 3H), 7.29-7.24 (m, 7H), 7.20-7.17 (m, 4H), 6.99 (d, *J* = 8.4 Hz, 1H), 6.89 (s, 1H), 5.70 (d, *J* = 4.0 Hz, 2H), 4.89 (s, 1H), 3.98 (AB, *J* = 14.8 Hz, 1H), 3.89 (s, 3H), 3.85 (AB, *J* = 14.8 Hz, 1H), 3.63 (t, *J* = 9.4 Hz, 1H), 3.45 (s, 3H), 2.90 (d, *J* = 9.6 Hz, 1H), 2.79 (t, *J* = 9.2 Hz, 1H), 2.41 (d, *J* = 10.0 Hz, 1H), 2.18 (s, 6H), 2.10 (s, 3H), 1.80 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 191.4, 158.8, 147.8, 142.5, 141.3, 140.0, 139.0, 138.2, 138.0, 133.4, 132.6, 131.9, 131.4, 130.3, 129.3, 129.2, 128.7, 128.4, 128.24, 128.16, 127.84, 127.55, 127.2, 126.7, 126.6, 126.1, 125.9, 125.6, 125.6, 125.44, 125.40, 124.8, 119.5, 112.1, 81.7, 74.0, 58.6, 55.2, 54.5, 54.1, 49.7, 40.6, 37.1, 35.3, 34.9, 29.1 ppm. HRMS (ESI) *m/z*: [M-H]⁻ calcd. for C₅₉H₅₅N₆O₃: 895.4341; found: 895.4353.



(*S*)-2-(2-(4-(4-(3-benzyl-5-(1-methyl-1H-imidazole-2-carbonyl)-1-phenyl-2-oxa-3azabicyclo[3.1.1]heptan-4-yl)phenyl)-1H-1,2,3-triazol-1-yl)ethyl)dibenzo[b,e]oxepin-11(6H)-one (12): Prepared from (*S*)-(3-benzyl-4-(4-ethynylphenyl)-1-phenyl-2-oxa-3azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)methanone (**3as**, 20.0 mg, 0.042 mmol) and 2-(2-azidoethyl)dibenzo[b,e]oxepin-11(6H)-one (17.6 mg, 0.063 mmol) according to the **GP4** at rt for 5 h. Purification by flash chromatography on silica gel using EtOAc afforded **12** as a colorless oil (31.6 mg, 99% yield).

12: **R**_{*f*} = 0.2 (petroleum ether/EtOAc = 1/1). [α]_D²⁰ = +10.0 (*c* = 0.50, CHCl₃). ¹**H NMR** (600 MHz, CDCl₃): δ 8.07 (d, *J* = 2.4 Hz, 1H), 7.87 (d, *J* = 7.8, 1H), 7.58-7.55 (m, 3H), 7.50-7.47 (m, 2H), 7.37-7.36 (m, 3H), 7.31-7.28 (m, 5H), 7.26-7.16 (m, 7H), 6.97 (d, *J* = 8.4 Hz, 1H), 6.90 (s, 1H), 5.18 (s, 2H), 4.90 (s, 1H), 4.62 (t, *J* = 7.2 Hz, 2H), 4.01 (AB, *J* = 14.8 Hz, 1H), 3.87 (AB, *J* = 14.8 Hz, 1H), 3.65 (t, *J* = 9.0 Hz, 1H), 3.46 (s, 3H), 3.26 (t, *J* = 7.2 Hz, 2H), 2.92 (d, *J* = 9.6 Hz, 1H), 2.81 (t, *J* = 9.0 Hz, 1H), 2.43 (d, *J* = 9.6 Hz, 1H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 191.5, 190.9, 160.4, 147.2, 142.5, 141.3, 140.3, 138.12, 138.06, 135.8, 135.5, 132.9, 131.6, 130.6, 130.3, 129.5, 129.3, 129.2, 128.7, 128.4, 128.2, 127.9, 127.6, 126.7, 126.1, 125.5, 125.4, 125.3, 121.3, 119.8, 81.7, 74.0, 73.6, 58.6, 54.1, 51.5, 49.7, 35.7, 35.3, 35.0 ppm. **HRMS** (ESI) *m/z*: [M+K]⁺ calcd. for C₄₇H₄₀N₆O₃K: 791.2743; found: 791.2746.



C₃₉H₃₇N₅O₃S M = 655.82 g/mol (3*R*,7*aS*)-3-(6-((2*S*,4*R*,5*R*)-4,5-diphenyl-1-tosylimidazolidin-2-yl)pyridin-2-yl)-2-phenylhexahydro-1H-pyrrolo[1,2-c]imidazol-1-one: (L9) Prepared from (*S*)-*N*-phenylpyrrolidine-2carboxamide (247.3 mg, 1.3 mmol, 1.0 equiv) according to the **GP5**. Purification by flash chromatography on silica gel afforded **L9** as a white solid (385 mg, 45% yield over 2 steps).

R_f = 0.5 (petroleum ether/EtOAc = 1/3). ¹**H NMR** (400 MHz, CDCl₃): δ 7.92 (d, *J* = 7.6 Hz, 1H), 7.83 (t, *J* = 7.6 Hz, 1H), 7.61 (d, *J* = 8.0 Hz, 2H), 7.38-7.33 (m, 3H), 7.22-7.06 (m, 10H), 7.01 (d, *J* = 7.2 Hz, 2H), 6.93 (t, *J* = 7.2 Hz, 1H), 6.86 (d, *J* = 7.2 Hz, 2H), 5.87 (s, 1H), 5.75 (s, 1H), 4.53 (d, *J* = 6.8 Hz, 1H), 4.14-4.08 (m, 2H), 3.49-3.40 (m, 2H), 2.92 (q, *J* = 8.4 Hz, 1H), 2.42 (s, 3H), 2.22-2.15 (m, 2H), 1.91-1.86 (m, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 174.6, 158.9, 157.6, 143.8, 139.2, 138.9, 138.3, 137.4, 134.0, 129.5, 128.8, 128.3, 128.1, 127.9, 127.5, 127.4, 127.2, 126.9, 125.0, 123.5, 121.2, 120.4, 84.2, 77.6, 71.9, 69.4, 64.8, 56.3, 27.8, 24.9, 21.5 ppm.



(3R,7aS)-2-(2,6-diethylphenyl)-3-(6-((2S,4R,5R)-4,5-diphenyl-1-tosylimidazolidin-2-yl)pyridin-2yl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one: (L10) Prepared from (S)-N-(2,6diethylphenyl)pyrrolidine-2-carboxamide (1.88 g, 10.0 mmol, 1.0 equiv) according tothe**GP5**. Purification by flash chromatography on silica gel afforded L10 as a whitesolid (1.10 g, 52% yield over 2 steps).

R_f = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.83 (t, J = 7.6 Hz, 1H), 7.68 (t, J = 7.2 Hz, 2H), 7.38 (d, J = 7.6 Hz, 2H), 7.25-7.15 (m, 8H), 7.06 (d, J = 7.6 Hz, 2H), 6.98-6.93 (m, 3H), 6.87 (d, J = 7.6 Hz, 1H), 6.76 (d, J = 7.2 Hz, 1H), 5.52 (s, 1H), 5.40 (s, 1H), 4.62 (d, J = 4.4 Hz, 1H), 4.29-4.26 (m, 1H), 4.10 (d, J = 4.4 Hz, 1H), 3.51-3.45 (m, 1H), 3.12-3.06 (m, 1H), 2.66-2.56 (m, 2H), 2.53-2.44 (m, 1H),

2.36 (s, 3H), 2.33-2.27 (m, 1H), 2.26-2.18 (m, 1H), 2.05-1.94 (m, 2H), 1.84-1.75 (m, 1H), 1.26-1.18 (m, 1H), 1.13 (t, *J* = 7.6 Hz, 3H), 0.72 (t, *J* = 7.6 Hz, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 173.8, 158.0, 157.2, 143.4, 142.7, 141.2, 140.5, 140.1, 137.8, 134.2, 132.0, 129.3, 128.3, 128.2, 128.0, 127.6, 127.3, 127.1, 127.0, 126.5, 126.2, 126.1, 123.8, 121.3, 85.4, 78.2, 71.1, 69.4, 65.0, 56.9, 29.0, 25.5, 24.9, 22.7, 21.5, 14.6, 13.5 ppm.



(*3R*,7*aS*)-2-(2,6-diisopropylphenyl)-3-(6-((2*S*,4*R*,5*R*)-4,5-diphenyl-1-tosylimidazolidin-2-yl)pyridin-2-yl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one: (L11) Prepared from (*S*)-*N*-(2,6diisopropylphenyl)pyrrolidine-2-carboxamide (274.4 mg, 1.0 mmol, 1.0 equiv) according to the **GP5**. Purification by flash chromatography on silica gel afforded **L11** as a white solid (273.5 mg, 37% yield over 2 steps).

R_f = 0.4 (petroleum ether/EtOAc = 1/3). ¹**H NMR** (400 MHz, CDCl₃): δ 7.86 (t, *J* = 7.6 Hz, 1H), 7.79 (d, *J* = 7.6 Hz, 1H), 7.71 (d, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 8.0 Hz, 2H), 7.20-7.09 (m, 10H), 7.05 (t, *J* = 7.6 Hz, 1H), 6.94-6.86 (m, 4H), 5.62 (s, 1H), 5.31 (s, 1H), 4.47 (d, *J* = 6.0 Hz, 1H), 4.35-4.32 (m, 1H), 4.15 (d, *J* = 6.4 Hz, 1H), 3.44-3.38 (m, 1H), 3.07-3.01 (m, 1H), 2.93-2.88 (m, 1H), 2.83 (s, br, 1H), 2.41 (s, 3H), 2.33-2.26 (m, 1H), 2.24-2.15 (m, 2H), 2.04-1.90 (m, 2H), 1.11 (d, *J* = 6.8 Hz, 3H), 1.05 (d, *J* = 6.8 Hz, 3H), 0.97 (d, *J* = 6.8 Hz, 3H), 0.21 (d, *J* = 6.8 Hz, 3H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 174.1, 158.2, 157.8, 147.9, 146.0, 143.7, 139.7, 139.6, 138.0, 133.9, 129.9, 129.5, 128.9, 128.2, 128.1, 127.8, 127.4, 127.3, 127.2, 126.7, 123.9, 123.7, 123.5, 121.7, 87.1, 77.8, 71.7, 69.5, 65.2, 56.9, 29.3, 29.0, 28.8, 25.4, 25.0, 24.8, 23.2, 22.6, 21.5 ppm.



(3*R*,7*aS*)-3-(6-((2*S*,4*R*,5*R*)-4,5-diphenyl-1-tosylimidazolidin-2-yl)pyridin-2-yl)-2-(naphthalen-1yl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one: (L12) Prepared from (*S*)-*N*-(naphthalen-1yl)pyrrolidine-2-carboxamide (576.7 mg, 2.4 mmol, 1.0 equiv) according to the **GP5**. Purification by flash chromatography on silica gel afforded **L12** as a white solid (241.0 mg, 14% yield over 2 steps).

R_{*t*} = 0.35 (petroleum ether/EtOAc = 5/1). ¹**H NMR** (400 MHz, CDCl₃): δ 7.86 (d, *J* = 8.0 Hz, 1H), 7.77 (t, *J* = 8.0 Hz, 1H), 7.72 (d, *J* = 7.6 Hz, 1H), 7.64-7.56 (m, 4H), 7.38-7.32 (m, 3H), 7.21-7.13 (m, 8H), 7.06 (d, *J* = 7.6 Hz, 3H), 6.86 (d, *J* = 7.2 Hz, 3H), 5.69 (s, 1H), 5.62 (s, 1H), 4.53 (d, *J* = 6.4 Hz, 1H), 4.45-4.42 (m, 1H), 4.05 (d, *J* = 6.4 Hz, 1H), 3.57-3.52 (m, 1H), 3.25-3.19 (m, 1H), 3.06 (s, br, 1H), 2.42 (s, 3H), 2.34-2.27 (m, 2H), 2.10-2.01 (m, 2H) ppm. ¹³**C NMR** (100 MHz, CDCl₃): δ 175.1, 158.7, 156.0, 143.8, 139.6, 139.0, 138.0, 134.3, 133.9, 132.3, 130.0, 129.5, 128.6, 128.4, 128.3, 128.2, 127.9, 127.5, 127.4, 127.0, 126.9, 126.7, 126.2, 125.3, 123.7, 121.9, 121.2, 86.6, 77.7, 71.7, 69.5, 65.1, 56.9, 28.4, 25.4, 21.5 ppm.



R_f = 0.3 (petroleum ether/EtOAc = 2/1). ¹**H NMR** (600 MHz, CDCl₃): δ 8.14 (d, J = 8.6 Hz, 2H), 7.98-7.95 (m, 4H), 7.55-7.52 (m, 2H), 7.31-7.25 (m, 4H), 6.72 (t, J = 8.6 Hz, 4H), 6.53 (dd, J = 8.6, 5.6 Hz, 4H), 5.04 (dd, J = 10.0, 8.2 Hz, 2H), 4.24 (dd, J = 10.2, 8.4 Hz, 2H), 3.67 (t, J = 8.4 Hz, 2H) ppm. ¹³**C NMR** (150 MHz, CDCl₃): δ 165.0, 161.8
(d, J = 243 Hz), 138.2, 138.1, 134.5, 132.9, 127.93 (d, J = 6 Hz), 127.86, 127.8, 127.1, 127.0, 126.7, 126.1, 125.6, 115.0 (d, J = 21 Hz), 74.3, 69.3 ppm. ¹⁹**F NMR** (565 MHz, CDCl₃) δ -115.87 ppm. **HRMS** (ESI) m/z: [M+H]⁺ calcd. for C₃₈H₂₇F₂N₂O₂: 581.2035; found: 581.2032.

3. X-Ray Crystallography

Supplementary Table 3. Crystal data and structure refinement of compound 3ao

Crystallographic files (CDCC: 2345666). There are no A-alerts and B-alerts, see CIF/checkCIF). The crystals are grown by slow solvent ($CH_2Cl_2/Et_2O/n$ -Hexane) evaporation at room temperature. CCDC number of (*S*)-(3-benzyl-4-(4-bromophenyl)-1-phenyl-2-oxa-3-azabicyclo[3.1.1]heptan-5-yl)(1-methyl-1H-imidazol-2-yl)methanone **3ao** (>99% *ee*) is 2345666. Flack parameter of **3ao**: 0.116(7)



Datablock: cu_2024031102_0m

Bond precision:	C-C = 0.0133 A	Wavelength=1.54178	
Cell:	a=10.0277(2) alpha=90	b=10.9571(3 beta=90	3) c=26.1879(7) gamma=90
Temperature:	150 K		
	Calculated	Rep	ported
Volume	2877.38(12)	287	77.38(12)
Space group	P 21 21 21	P 2	21 21 21
Hall group	P 2ac 2ab	P 2	2ac 2ab
Moiety formula	C29 H26 Br N3 O2 [solvent]	+ C29	9 H26 Br N3 O2
Sum formula	C29 H26 Br N3 O2 [solvent]	+ C29	9 H26 Br N3 O2
Mr	528.43	528	3.44
Dx, g cm-3	1.220	1.2	220
Z	4	4	
Mu (mm-1)	2.162	2.1	162
F000	1088.0	1088.0	
F000'	1087.99		
h,k,lmax	12,13,31	12,	13,31
Nref	5262[2994]	524	17
Tmin, Tmax	0.802,0.933	0.5	539,0.753
Tmin'	0.467		
Correction method= # Reported T Limits: Tmin=0.539 Tmax=0.753			
AbsCorr = MULTI-SCAN			

Data completeness= 1.75/1.00 Theta(max)= 68.329

4. Supplementary NMR and HPLC Spectra



Supplementary Figure 8. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1a



Supplementary Figure 9. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1a









Supplementary Figure 13. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1c



Supplementary Figure 14. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1d



Supplementary Figure 15. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1d



Supplementary Figure 16. ¹⁹F NMR (376 MHz, CDCI₃) spectrum of compound 1d



Supplementary Figure 17. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1e



Supplementary Figure 18. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1e



Supplementary Figure 19. ¹⁹F NMR (376 MHz, CDCl₃) spectrum of compound 1e



Supplementary Figure 20. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1f



Supplementary Figure 21. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1f



Supplementary Figure 22. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1g



Supplementary Figure 23. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1g



Supplementary Figure 24. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1h



Supplementary Figure 25. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1h





Supplementary Figure 27. ¹³C NMR (100 MHz, CDCI₃) spectrum of compound 1i



Supplementary Figure 28. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1j



Supplementary Figure 29. ¹³C NMR (100 MHz, CDCI₃) spectrum of compound 1j



Supplementary Figure 30. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1k



Supplementary Figure 31. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1k



Supplementary Figure 32. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1I



Supplementary Figure 33. ¹³C NMR (100 MHz, CDCI₃) spectrum of compound 1I



Supplementary Figure 34. ¹H NMR (400 MHz, CDCI₃) spectrum of compound 1m



Supplementary Figure 35. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1m



Supplementary Figure 36. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 1q



Supplementary Figure 37. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 1q





Supplementary Figure 39. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3aa



Supplementary Figure 40. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ab



Supplementary Figure 41. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ab



Supplementary Figure 42. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ac



Supplementary Figure 43. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ac



Supplementary Figure 44. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ad



Supplementary Figure 45. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ad



Supplementary Figure 46. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ae



Supplementary Figure 47. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ae



Supplementary Figure 48. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3af



Supplementary Figure 49. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3af



Supplementary Figure 50. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ag



Supplementary Figure 51. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ag



Supplementary Figure 53. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ah



Supplementary Figure 54. ¹H NMR (400 MHz, CDCI₃) spectrum of compound 3ai



Supplementary Figure 55. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ai



Supplementary Figure 56. ¹H NMR (400 MHz, CDCI₃) spectrum of compound 3aj



Supplementary Figure 57. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3aj



Supplementary Figure 58. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ak



Supplementary Figure 59. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ak





20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2: f1 (ppm)

Supplementary Figure 60. ¹⁹F NMR (376 MHz, CDCI₃) spectrum of compound 3ak



Supplementary Figure 61. ¹H NMR (400 MHz, CDCI₃) spectrum of compound 3al



Supplementary Figure 62. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3al



Supplementary Figure 63. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3am



Supplementary Figure 64. $^{\rm 13}C$ NMR (100 MHz, CDCl_3) spectrum of compound 3am

¹H and ¹³C NMR Spectra for Compound 3an:



Supplementary Figure 65. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3an



Supplementary Figure 66. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3an



Supplementary Figure 67. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ao



Supplementary Figure 68. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ao



Supplementary Figure 69. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ap



Supplementary Figure 70. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ap

 $\begin{array}{c} 7.36(1) \\ 7.339$



Supplementary Figure 71. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3aq



Supplementary Figure 72. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3aq



Supplementary Figure 73. ¹⁹F NMR (376 MHz, CDCI₃) spectrum of compound 3aq



Supplementary Figure 74. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ar



Supplementary Figure 75. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ar


Supplementary Figure 76. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3as



Supplementary Figure 77. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3as



Supplementary Figure 78. ¹H NMR (400 MHz, CDCI₃) spectrum of compound 3at



Supplementary Figure 79. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3at



Supplementary Figure 80. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3au



Supplementary Figure 81. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3au



Supplementary Figure 82. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3av



Supplementary Figure 83. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3av



Supplementary Figure 84. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3aw



Supplementary Figure 85. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3aw



Supplementary Figure 86. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ax



Supplementary Figure 87. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ax



Supplementary Figure 88. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ay



Supplementary Figure 89. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ay



Supplementary Figure 90. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3az



Supplementary Figure 91. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3az



Supplementary Figure 92. ¹H NMR (600 MHz, CDCl₃) spectrum of compound 3aaa



Supplementary Figure 93. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3aaa



Supplementary Figure 95. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound

3abb



Supplementary Figure 96. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3bb



Supplementary Figure 97. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3bb



Supplementary Figure 98. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3cb



Supplementary Figure 99. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3cb



3db



Supplementary Figure 102. ¹⁹F NMR (376 MHz, CDCl₃) spectrum of compound **3db**



Supplementary Figure 103. ¹H NMR (600 MHz, CDCl₃) spectrum of compound 3eb



Supplementary Figure 104. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3eb



Supplementary Figure 105. ¹⁹F NMR (565 MHz, CDCl₃) spectrum of compound 3eb



Supplementary Figure 107. ¹³C NMR (100 MHz, CDCI₃) spectrum of compound 3fb



Supplementary Figure 108. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3gb



Supplementary Figure 109. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3gb



Supplementary Figure 110. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3hb



Supplementary Figure 111. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3hb



Supplementary Figure 112. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ib



Supplementary Figure 113. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ib





Supplementary Figure 114. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3jb



Supplementary Figure 115. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3jb



Supplementary Figure 116. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3kb



Supplementary Figure 117. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3kb



Supplementary Figure 118. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3lb



Supplementary Figure 119. ¹³C NMR (100 MHz, CDCI₃) spectrum of compound 3lb



Supplementary Figure 120. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3mb



Supplementary Figure 121. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3mb



Supplementary Figure 123. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound

3nb



Supplementary Figure 124. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3ob



Supplementary Figure 125. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3ob



Supplementary Figure 126. ¹⁹F NMR (376 MHz, CDCl₃) spectrum of compound 3ob



Supplementary Figure 127. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3pb



Supplementary Figure 128. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3pb



Supplementary Figure 129. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 3qb



Supplementary Figure 130. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3qb



Supplementary Figure 131. ¹⁹F NMR (376 MHz, CDCl₃) spectrum of compound 3qb



Supplementary Figure 133. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 3rb



Supplementary Figure 135. ¹³C NMR (150 MHz, CDCl₃) spectrum of compound 4nb



Supplementary Figure 137. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 4qb



20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2; f1 (ppm)

Supplementary Figure 138. ¹⁹F NMR (376 MHz, CDCl₃) spectrum of compound 4qb



Supplementary Figure 139. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 5



Supplementary Figure 140. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 5



Supplementary Figure 141. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 6



Supplementary Figure 142. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 6



Supplementary Figure 143. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 7



Supplementary Figure 144. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 7



Supplementary Figure 145. ¹H NMR (400 MHz, CDCl₃) spectrum of compound 8



Supplementary Figure 146. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 8



Supplementary Figure 147. ¹H NMR (600 MHz, CDCl₃) spectrum of compound 9


Supplementary Figure 148. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 9



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)

Supplementary Figure 149. ¹⁹F NMR (565 MHz, CDCl₃) spectrum of compound 9



Supplementary Figure 150. ¹H NMR (600 MHz, CDCl₃) spectrum of compound 10



Supplementary Figure 151. ¹³C NMR (150 MHz, CDCl₃) spectrum of compound 10



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)

Supplementary Figure 152. ¹⁹F NMR (565 MHz, CDCl₃) spectrum of compound 10



Supplementary Figure 153. ¹H NMR (600 MHz, CDCl₃) spectrum of compound 11



D.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0 f1 (ppm)

1.93∕ 0.99<u>≖</u> 1.97,

0.96°

4

00.1

Supplementary Figure 155. ¹H NMR (600 MHz, CDCl₃) spectrum of compound 12



Supplementary Figure 156. ¹³C NMR (100 MHz, CDCl₃) spectrum of compound 12











Supplementary Figure 160. HPLC spectra of (rac)-3aa and (S)-3aa



Supplementary Figure 161. HPLC spectra of (rac)-3ab and (S)-3ab



Supplementary Figure 162. HPLC spectra of (rac)-3ac and (S)-3ac



Supplementary Figure 163. HPLC spectra of (rac)-3ad and (S)-3ad



Supplementary Figure 164. HPLC spectra of (rac)-3ae and (S)-3ae



Supplementary Figure 165. HPLC spectra of (rac)-3af and (S)-3af



Supplementary Figure 166. HPLC spectra of (*rac*)-3ag and (*S*)-3ag



Supplementary Figure 167. HPLC spectra of (rac)-3ah and (S)-3ah



Supplementary Figure 168. HPLC spectra of (rac)-3ai and (S)-3ai



Supplementary Figure 169. HPLC spectra of (rac)-3aj and (S)-3aj



Supplementary Figure 170. HPLC spectra of (*rac*)-3ak and (S)-3ak



Supplementary Figure 171. HPLC spectra of (rac)-3al and (S)-3al



Supplementary Figure 172. HPLC spectra of (rac)-3am and (S)-3am



Supplementary Figure 173. HPLC spectra of (rac)-3an and (S)-3an



Supplementary Figure 174. HPLC spectra of (rac)-3ao and (S)-3ao



Supplementary Figure 175. HPLC spectra of (*rac*)-**3ap** and (*S*)-**3ap**



Supplementary Figure 176. HPLC spectra of (rac)-3aq and (S)-3aq



Supplementary Figure 177. HPLC spectra of (rac)-3ar and (S)-3ar



Supplementary Figure 178. HPLC spectra of (rac)-3as and (S)-3as



Supplementary Figure 179. HPLC spectra of (rac)-3at and (S)-3at



Supplementary Figure 180. HPLC spectra of (rac)-3au and (S)-3au



Supplementary Figure 181. HPLC spectra of (rac)-3av and (S)-3av



Supplementary Figure 182. HPLC spectra of (rac)-3aw and (S)-3aw



Supplementary Figure 183. HPLC spectra of (*rac*)-3ax and (*R*)-3ax



Supplementary Figure 184. HPLC spectra of (*rac*)-3ay and (*R*)-3ay



Supplementary Figure 185. HPLC spectra of (rac)-3az and (R)-3az



Supplementary Figure 186. HPLC spectra of (rac)-3aaa and (S)-3aaa



Supplementary Figure 187. HPLC spectra of (rac)-3abb and (S)-3abb



Supplementary Figure 188. HPLC spectra of (rac)-3bb and (S)-3bb



Supplementary Figure 189. HPLC spectra of (rac)-3cb and (S)-3cb


Supplementary Figure 190. HPLC spectra of (rac)-3db and (S)-3db



Supplementary Figure 191. HPLC spectra of (rac)-3eb and (S)-3eb



Supplementary Figure 192. HPLC spectra of (rac)-3fb and (S)-3fb



Supplementary Figure 193. HPLC spectra of (rac)-3gb and (S)-3gb



Supplementary Figure 194. HPLC spectra of (rac)-3hb and (S)-3hb



Supplementary Figure 195. HPLC spectra of (rac)-3ib and (S)-3ib



Supplementary Figure 196. HPLC spectra of (rac)-3jb and (S)-3jb



Supplementary Figure 197. HPLC spectra of (rac)-3kb and (S)-3kb



Supplementary Figure 198. HPLC spectra of (*rac*)-3lb and (S)-3lb



Supplementary Figure 199. HPLC spectra of (rac)-3mb and (S)-3mb



Supplementary Figure 200. HPLC spectra of (rac)-3nb and (S)-3nb



Supplementary Figure 201. HPLC spectra of (rac)-3ob and (S)-3ob



Supplementary Figure 202. HPLC spectra of (rac)-3pb and (S)-3pb



Supplementary Figure 203. HPLC spectra of (rac)-3qb and (S)-3qb



Supplementary Figure 204. HPLC spectra of (rac)-4nb and (S)-4nb



Supplementary Figure 205. HPLC spectra of (*rac*)-**5** and (*S*)-**5**



Supplementary Figure 206. HPLC spectra of (*rac*)-6 and (*S*)-6



Supplementary Figure 207. HPLC spectra of (*rac*)-7 and (S)-7



Supplementary Figure 208. HPLC spectra of (rac)-3nd and (S)-3nd



Supplementary Figure 209. HPLC spectra of (rac)-3qb and (S)-3qb

5. Supplementary Computational Details

In order to understand the origin of enantioselectivity, density functional theory (DFT) calculations were carried out using the Gaussian 09 software package.^[13-16] The spin-quartet state was calculated for the cobalt(II) complexes because of the high-spin state with lower energy. The stationary structures were optimized using PBE0 method and combined basis set. That is, SDD for Co atom, and 6-31G(d) basis set for all the other atoms.^[17] Truhlar and coworkers' SMD solvation model was employed to consider the solvent effect of Dichloromethane.^[18] The geometry optimizations were performed without symmetry constraints, and the nature of the extrema was checked by analytical frequency calculations. The intrinsic reaction coordinate (IRC)^[19] pathways have been traced to verify two desired minima connected by the transition states. The independent gradient model based on Hirshfeld partition (IGMH) analysis was conducted with Multiwfn and VMD.^[20-22] The 3-D images of the calculated structures were prepared using CYLview.^[23]

Note: source data are provided with this paper

6. Supplementary References

- Dhake, K., Woelk, K. J., Becica, J., Un, A., Jenny, S. E. & Leitch, D. C., Beyond Bioisosteres: Divergent Synthesis of Azabicyclohexanes and Cyclobutenyl Amines from Bicyclobutanes. *Angew. Chem. Int. Ed.* 61, e202204719 (2022).
- Livingstone, K. et al. Skeletal Ring Contractions via I(I)/I(III) Catalysis: Stereoselective Synthesis of cis-α,α-Difluorocyclopropanes. ACS Catal. 12, 14507-14516 (2022).
- Guo, R. et al. Strain-Release [2π+2σ] Cycloadditions for the Synthesis of Bicyclo[2.1.1]hexanes Initiated by Energy Transfer. *J. Am. Chem. Soc.* 144, 7988-7994 (2022).

- Sharland, J. C. & Davies, H. M. L., One-Pot Synthesis of Difluorobicyclo[1.1.1]pentanes from α-Allyldiazoacetates. *Org. Lett.* 25, 5214-5219 (2023).
- Poulsen, P. H., Vergura, S., Monleon, A., Jørgensen, D. K. B. & Jørgensen, K. A. Controlling Asymmetric Remote and Cascade 1,3-Dipolar Cycloaddition Reactions by Organocatalysis. *J. Am. Chem. Soc.* **138**, 6412-6415 (2016).
- Matassini, C., Parmeggiani, C., Cardona, F. & Goti, A., Oxidation of N,N-Disubstituted Hydroxylamines to Nitrones with Hypervalent Iodine Reagents. *Org. Lett.* 17, 4082-4085 (2015).
- Chen, X., Cheng, Z., Guo, J. & Lu, Z., Asymmetric remote C-H borylation of internal alkenes via alkene isomerization. *Nat. Commun.* 9, 3939 (2018).
- Wang, X.-B. et al. Rational Design of Chiral Tridentate Ligands: Bifunctional Cobalt(II) Complex/Hydrogen Bond for Enantioselective Michael Reactions. *Org. Lett.* 24, 3861-3866 (2022).
- Wang, H.-X. et al. Design of C₁-symmetric tridentate ligands for enantioselective dearomative [3 + 2] annulation of indoles with aminocyclopropanes. *Nat. Commun.* 14, 2270 (2023).
- Wang, X.-Y. et al. Cobalt-Catalyzed Asymmetric Dearomative [3 + 2] Annulation of Quinolines, Isoquinolines, and Pyridines. ACS Catal. 13, 11528–11540 (2023).
- Zhang, J., Su, J.-Y., Zheng, H., Li, H. & Deng, W.-P., Eu(OTf)₃-Catalyzed Formal Dipolar [4π+2σ] Cycloaddition of Bicyclo-[1.1.0]butanes with Nitrones: Access to Polysubstituted 2-Oxa-3-azabicyclo[3.1.1]heptanes. *Angew. Chem. Int. Ed.* 63, e202318476 (2024).
- 12. Liang, Y., Paulus, F., Daniliuc, C. G. & Glorius, F. Catalytic Formal [2π+2σ] Cycloaddition of Aldehydes with Bicyclobutanes: Expedient Access to

Polysubstituted 2-Oxabicyclo[2.1.1]hexanes. *Angew. Chem. Int. Ed.* **62**, e202305043 (2023).

- Becke, A. D., Density-functional thermochemistry. III. The role of exact exchange.
 J. Chem. Phys. 98, 5648 (1993).
- Stephens, P. J., Devlin, F. J., Chabalowski, C. F. & Frisch, M. J., Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields. *J. Phys. Chem.* **98**, 11623 (1994).
- 15. Lee, C., Yang, W. & Parr, R. G., Development of the Colle-Salvetti correlationenergy formula into a functional of the electron density. *Phys. Rev. B* **37**, 785 (1998).
- Frisch, M. J. et al. Gaussian 09, Revision A.02; Gaussian, Inc.: Wallingford, CT, 2009.
- Hay, P. J. & Wadt, W. R., Ab initio effective core potentials for molecular calculations. Potentials for the transition metal atoms Sc to Hg. *J. Chem. Phys.* 82, 270 (1985).
- Marenich, A. V., Cramer, C. J. & Truhlar, D. G., Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions. *J. Phys. Chem. B* **113**, 6378 (2009).
- Fukui, K., Formulation of the reaction coordinate. J. Phys. Chem. 74, 4161-4163 (1970).
- Johnson, E. R. et al. Revealing Noncovalent Interactions. J. Am. Chem. Soc. 132, 6498-6506 (2010).
- Lu, T. & Chen, F., Multiwfn: A multifunctional wavefunction analyzer. *J. Comput. Chem.* 33, 580-592 (2012).

- 22. Humphrey, W., Dalke, A. & Schulten, K., VMD: Visual molecular dynamics. *J. Mol. Graphics.* **14**, 33-38 (1996).
- 23. Legault, C. Y. C., 1.0b; Universitéde Sherbrooke: Québec, Montreal, Canada; 2009, http://www.cylview.org.